Medivir announces Janssen decision to terminate its simeprevir license effective June 2018

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Pharmaceuticals Inc. (Janssen) has decided to terminate the license that it holds for simeprevir due to Janssen’s assessment of market demand. The termination of the license will become effective in June 2018 and Medivir will continue to receive royalties on any remaining sales of Olysio/Sovriad (simeprevir) that Janssen will make until that time. Medivir will seek to identify potential commercialization partners for specific territories where it believes there may be a market opportunity. Medivir’s royalty on the global sales of simeprevir in the first three quarters of 2017 were SEK 13.7M, SEK 7.7M, and SEK 4.1M respectively. For further information, please contact:Christine Lind, CEO Medivir AB, phone: +46 (0)8 407 4641Anders Lundin, CFO Medivir AB, phone: +46 (0)73 125 1453 This is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 11.30 CET on 10 December 2017. About MedivirMedivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo® (melflufen) at the 59th Annual Meeting of ASH today

Summary of key results presentedThe results show a median progression-free survival (PFS) of 5.7 months, a median overall survival (OS) of 20.7 months and an overall response rate of 31%. The data are very encouraging and compares favorably with other clinical studies in this patient population. CEO comments on O-12-M1“Myeloma patients that primarily are treated with lenalidomide and proteasome inhibitors through several lines of therapy and suffer from disease progression in conjunction with treatment have deteriorating prognosis and a significant medical need. In the clinical study O-12-M1, we have studied the efficacy of Ygalo® in these advanced stage patients. The results show a median OS of 20.7 months, median PFS of 5.7 months and ORR of 31%. Tolerability profile was good with patients receiving monthly doses of Ygalo® for a median of 5 cycles. These data compare favorably with other clinical studies in this patient group, especially when considering that 44% of patients in O-12-M1 also had failed on pomalidomide. The data provides us with an increasing degree of comfort regarding the outcome of our Phase III program OCEAN and a role for Ygalo® in the treatment of late-stage myeloma patients" said Jakob Lindberg, CEO of Oncopeptides.  The poster presented at ASH can be found at: www.oncopeptides.se/presentations/ASH  Conference call for investors, analysts and the mediaJakob Lindberg, CEO at Oncopeptides will summarize impressions from the ASH Annual Meeting and will review and comment on relevant data from the conference including a summary of the survival data from the   O-12-M1 study and interim data from the ongoing HORIZON study. Time: Wednesday, 13th December 2017, at 14.30 (CET).Phone numbers for participants from:UK: +44 2030089801SE: +46 856642662US: +1 8557532235 The conference call will also be streamed via a link on the website: www.oncopeptides.se and the presentation will be available on Oncopeptides website after completion of the telephone conference. About the O-12-M1 study EnrolmentPatient enrolment in the study was completed in December 2016. In total, 45 patients were included with data cut-off of 9th November 2017. One patient was still in treatment at time of data cut-off. MethodsYgalo® (Melflufen) 40 mg was administered intravenously on Day 1 of each 28-day cycle together with dexamethasone 40 mg weekly for up to 8 cycles or longer. Patients had relapsed-refractory MM (RRMM) with measurable disease, ≥2 prior lines of therapy including lenalidomide and bortezomib, and disease progression on or within 60 days of completion of last therapy. After disease progression (PD) or start of subsequent therapy, patients were followed for survival every 3 months for up to 24 months. The median number of prior lines of therapy was four. Of the treated patients, 64% were double refractory immunomodulatory drugs (IMiDs) and a proteasome inhibitors (PIs), 93% were last line refractory and 44% were pomalidomide refractory. Patients were treated with a median of 5 cycles of Ygalo® and the median treatment duration was 16 weeks. Results - Efficacy conclusions regarding O-12-M1Treatment with Ygalo®, a peptidase enhanced Cytotoxics (PEnCs), shows long-term benefit in late-stage RRMM patients where conventional therapies have failed. Both the median PFS and OS in this heavily pre-treated population, with limited remaining treatment options, are encouraging, standing at 5.7 months and 20.7 months respectively. The long median OS of 30.2 months in patients that achieved stable disease (SD) as best response will be studied further in the ongoing studies OCEAN (phase III) and HORIZON (phase II). Overall response rate (efficacy evaluable and all treated patients) +-----------------------------+--+--+--+--+----+---+---+|N |PD|SD|MR|PR|VGPR|ORR|CBR|+-----------------------------+--+--+--+--+----+---+---+|ITT (N = 45)* |7 |12|8 |9 |5 |31%|49%|+-----------------------------+--+--+--+--+----+---+---+|Efficacy evaluable** (N = 34)|1 |11|8 |9 |5 |41%|65%|+-----------------------------+--+--+--+--+----+---+---+ *Four patients did not have a response assessment** patients receiving two doses of Ygalo® SafetyThe treatment was well tolerated in this late stage patient population. Reversible and clinically man­ageable hematologic toxicity was the most common AE type. Non-hematologic AEs were infrequent. About Ygalo®Ygalo® is a next generation alkylator compound that targets cancer cells through a mechanism called Peptidase Enhanced Cytotoxics (PEnCs). In cell culture studies, traditional alkylators target cancer cells (which treats the disease) and also bone marrow cells (which causes side effects) to an equal degree. In contrast, Ygalo® targets the myeloma cells 50x better than the bone-marrow cells.  Ygalo® in clinical developmentYgalo® has been used to treat late-stage RRMM patients in both phase I and phase II clinical studies with favorable results. Currently, Ygalo® is being studied in three clinical trials for the treatment of multiple myeloma. The current studies are O-12-M1, HORIZON and OCEAN. A fourth study, ANCHOR, will be initiated early 2018 to further investigate Ygalo® as part of combination therapies in multiple myeloma. About Multiple MyelomaMultiple myeloma is a hematological cancer of the B-cells (antibody producing cells) with no cure. Currently, the median overall survival is roughly 5 years and improving (Source: National Cancer Institute - US). Today, approximately 170,000 patients live with multiple myeloma in the EU and the US while 57,000 patients are newly diagnosed and 26,000 patients die from the disease annually (Source: American Cancer Society, Global Data 2015 and National Cancer Institute). The underlying increase in the number of multiple myeloma patients is slightly more than 1% per year where an aging population is the main reason for growth. However, the growth in late-stage multiple myeloma patients, that is the focus area for Ygalo®, is more than 10% per year due to improvements in earlier lines of therapy, i.e. more patients survive the first years with multiple myeloma and become late-stage, multi-refractory patients with a significant medical need for further treatment options. Treating Multiple MyelomaMultiple myeloma is mainly treated through five different treatment modalities – alkylators, CD-38 binding antibodies, IMiDs, proteasome inhibitors and steroids. Due to the high mutation frequency of myeloma cells, patients have several different active cancers (cancer cell clones) at the same time with different protein expression patterns. Because of this heterogeneity of the disease in each patient, broad spectrum agents such as alkylators, IMiDs, proteasome inhibitors and steroids are the back-bone in its treatment. In the case of the new targeted agents, they will predominantly be used in combination with broad spectrum agents to ensure that all the patient’s cancer cells are appropriately treated. Immuno-oncological compounds have so far had limited success in the treatment of the disease. About OncopeptidesOncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company, the focus has primarily been on the development of the lead product candidate Ygalo®, an innovative, Peptidase Enhanced Cytotoxics (PEnCs) intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma. The current clinical study program is intended to demonstrate better results from treatment with Ygalo® compared to established alternative drugs for patients with late-stage multiple myeloma. Ygalo® could potentially provide physicians with a new treatment option for patients suffering from this serious disease.Visit www.oncopeptides.se for more information. For further information, please contact:Jakob Lindberg, CEO of OncopeptidesE-mail: jakob.lindberg@oncopeptides.seRein Piir, Head of Investor Relations at OncopeptidesE-mail: rein.piir@oncopeptides.se The information in the press release is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person above, on December 10, 2017 at 15.00 p.m. (CET).

Starbreeze releases new cinematic trailer for OVERKILL’s the Walking Dead revealing the co-op action shooter’s first character, Aidan

A new cinematic trailer was released today for OVERKILL’s The Walking Dead, the upcoming cooperative first-person shooter in development by OVERKILL – A Starbreeze Studio, together with its partners Skybound Entertainment and 505 Games. This video features Aidan, the first of the game’s four unique playable characters fighting to stay alive in a post-apocalyptic world. Watch the trailer here: https://youtu.be/non_0jlOXew Inspired by the rich story universe of Robert Kirkman’s original graphic novels, OVERKILL’s The Walking Dead is a four-player co-op multiplayer FPS action game set in Washington, D.C., as an outbreak brings the dead back to life. In this test of strategy and endurance, players will band together with up to three friends on a variety of missions and raids, securing supplies and survivors to strengthen their base camp against the threat of both the dead and the living - by any means necessary. Each playable character has their own special abilities, skill trees, squad roles, play styles and background stories. Now they all share a common objective where survival and teamwork is paramount. The action is close-up and intense: take out enemies carefully with silent melee attacks or go in guns blazing. You need to be able to improvise, as nothing is certain, and a horde of walkers is always around the corner. OVERKILL’s The Walking Dead is expected to launch fall 2018 on the PlayStation®4, Xbox One™ and Windows PC. For the latest updates, visit https://www.overkillsthewalkingdead.com, and follow the game on Facebook , Twitter  and Instagram .  ###

Betalutin® shows strong clinical profile in relapsed/refractory indolent NHL and follicular lymphoma

Oslo, Norway, 11 December 2017 Nordic Nanovector ASA (OSE: NANO) has presented updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory (R/R) indolent NHL (iNHL) at the 59th Annual ASH meeting (9-12 December 2017 in Atlanta, GA, USA). A conference call and audio cast to present the results will take place today at 08:00 CET – details below. The updated data continue to highlight Betalutin®’s strong clinical profile as a single agent for treatment of R/R iNHL, and particularly of third-line R/R follicular lymphoma (3L FL), the primary patient population for which Betalutin® is initially being developed. Single-agent Betalutin® is effective and well-tolerated in patients with R/R iNHL: · 90% of all patients (n=59) had a reduction in tumour size · Overall response rate (ORR) of 60% and complete response (CR) of 24% for all evaluable iNHL patients · Highly active in patients with 2 or more prior therapies (3L FL) with 66% ORR and 25% CR · Encouraging results in FL patients:                      o Arm 1 40/15: 68% ORR and 28% CR                      o Arm 4 100/20: 50% ORR and 25% CR · Durable responses, especially for patients with a CR                     o 13.3 months for all iNHL patients                          ▪ 20.5 months for patients with CR                     o 13.3 months for FL patients treated with 40 mg lilotomab/15 MBq/kg Betalutin®                         ▪ 22.9 months for patients with CR As reported previously, Betalutin® treatment was well-tolerated with a safety profile characterized by reversible transient neutropenia and thrombocytopenia and a low incidence of infections. Dr Arne Kolstad, MD, Principal Investigator of the study, commented: “The data presented at ASH are very exciting. The combination of efficacy, tolerability and the convenience of a single administration highlight Betalutin®’s potential in this primarily elderly, heavily pre-treated patient population. Notably, the CRs seen in both Arm 1 and Arm 4 in FL patients and the duration of responses are very promising, and we look forward to treating more patients in the upcoming PARADIGME study.  Dr Lisa Rojkjaer, Chief Medical Officer of Nordic Nanovector, added: “We are very pleased about these data, which continue to demonstrate a strong clinical profile for Betalutin®, particularly in 3L FL patients. The CR rates are especially encouraging. This is a population of high unmet medical need for whom safe effective therapies are needed, and the Phase 2b PARADIGME trial will focus on these patients. The results obtained provide a strong foundation for this trial.” The poster has been published on Nordic Nanovector’s website (www.nordicnanovector.com) in the section: /what-we-do/scientific-background/scientific-posters. Conference call and audio cast details: Please join the conference 5-10 minutes prior to the start time. You will be asked to provide the confirmation code or the title of the conference. Event Conference Title:  Nordic Nanovector – ASH update Date and time:   Monday 11 December 2017 at 08:00 CET Confirmation Code:  2436440 +----------------------------------+----------------+|Location |Phone Number |+----------------------------------+----------------+|Norway |+47 2350 0296 |+----------------------------------+----------------+|Switzerland |+41 44 580 1022 |+----------------------------------+----------------+|Sweden |+46 8 5065 3942 |+----------------------------------+----------------+|United   Kingdom and International|+44 330 336 9411|+----------------------------------+----------------+|United States |+1 720-452-9217 |+----------------------------------+----------------+ The conference call presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Presentation/2017 from 08:00 CET on 11 December 2017. If you want to follow the presentation via audio cast with sound and slides, please use the following link:  http://webtv.hegnar.no/presentation.php?webcastId=75022840  For further information, please contact: IR enquiries: Tone Kvåle, Chief Financial Officer Cell: +47 91 51 95 76 Email: ir@nordicnanovector.com Media enquiries: Mark Swallow/David Dible/Marine Perrier (Citigate Dewe Rogerson) Tel: +44 207 638 9571 Email: nordicnanovector@citigatedewerogerson.com About Nordic Nanovector: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com Forward-looking statements This announcement may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector’s strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting

Bergen, Norway, 11 Dec 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, today announced that it presented an update on the BGBC003 clinical trial (NCT02488408) with selective AXL inhibitor BGB324 in patients with relapsed/refractory Acute Myeloid Leukaemia (AML) or Myeloid Dysplastic Syndrome (MDS). Clinical benefit was observed and three novel, proprietary predictive biomarker candidates were identified. Data showing the immune modulatory effect of BGB324 in this patient population was also reported. In a poster presentation at the 59th American Society of Hematology Annual Meeting in Atlanta entitled: “The orally available selective AXL inhibitor BGB324 induces diversification of the immune repertoire and specific changes in plasma biomarker profiles”, Professor Sonja Loges, attending physician at the University Hospital in Hamburg-Eppendorf and lead investigator of the BGBC003 trial, detailed the following: · 35 patients with relapsed/refractory AML or MDS received BGB324 monotherapy on the BGBC003 trial. Two patients achieved complete responses with incomplete heamatologic recovery (CRi) and five achieved partial responses (PR). Seven patients reported disease stabilisation for more than four months. Four patients remain on study at the time of data cut-off. · Three novel predictive biomarker candidates that correlated significantly with clinical benefit were detected in blood, bone marrow plasma or bone marrow cell samples from patients. · Over the course of treatment with BGB324, patients demonstrated a diversification of their T- and B-cell receptor repertoire in peripheral blood and/or bone marrow indicating immune activation upon BGB324 therapy. Professor Sonja Loges commented: ‘’Relapsed/refractory AML and MDS patients currently have no treatment options. Selective AXL inhibition holds particular promise as a potential new treatment modality as it blocks a key cancer survival mechanism in the bone marrow and acts as an activator of the immune system. I am extremely encouraged by these signs of clinical efficacy of BGB324 in these patients as well as the favourable safety profile observed.’’ Richard Godfrey, CEO of BerGenBio commented: “The BGBC003 trial in AML is one of six ongoing phase II trials evaluating our first-in-class selective AXL inhibitor BGB324. The observed clinical benefit with BGB324 monotherapy in AML and MDS is very encouraging. The second part of the trial, featuring expansion cohorts as a monotherapy as well as in combination with low dose chemotherapy is ongoing and we are looking forward to reporting an update in 2018. I am particularly encouraged with the biomarker data as this supports our clinical development strategy to enrich future clinical trials with patients most likely to benefit from therapy with BGB324’’. About AML   AML is the most common form of acute leukaemia in adults where malignant AML blasts interfere with the normal functioning of the bone marrow leading to a multitude of complications like anaemia, infections and bleeding. AML is diagnosed in over 20,000 patients in the US annually and is rapidly lethal if left untreated. Successful treatment typically requires intensive therapy or bone marrow transplantation, and relapse and resistance are common. Consequently, there is an urgent need for effective novel therapies in relapsed/refractory patients, particularly those that are ineligible for intensive therapy.  About the BGBC003 trial The BGBC003 trial is a phase Ib/II multi-centre open label study of BGB324 as a single agent in patients with AML or MDS or in a combination with cytarabine and decitabine in AML patients. Up to 75 patients will be enrolled at centres in the US, Norway, Germany and Italy. For more information please access trial NCT02488408 at www.clinicaltrials.gov. About the 59th ASH Annual Meeting in Atlanta, GA The 59th ASH Annual Meeting and Exposition is the most comprehensive haematology conference worldwide and attracts more than 25,000 haematology professionals from every subspecialty. About BerGenBio ASA   BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the essential role of AXL kinase in mediating cancer spread, immune evasion and drug resistance in multiple aggressive solid and haematological cancers. BerGenBio’s lead product, BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in four Company sponsored Phase II clinical trials in major cancer indications, with read-outs anticipated in the second half of 2018. It is the only selective AXL inhibitor in clinical development. The Company sponsored clinical trials are: · BGB324 as a single agent and combination therapy in acute myeloid leukaemia (AML) / myeloid dysplastic syndrome (MDS) · BGB324 with TARCEVA® (erlotinib) in advanced EGFR mutation driven non-small cell lung cancer (NSCLC) · BGB324 with KEYTRUDA in advanced adenocarcinoma of the lung, and · BGB324 with KEYTRUDA in triple negative breast cancer (TNBC). The clinical trials combining BGB324 with KEYTRUDA in adenocarcinoma of the lung and TNBC are conducted in collaboration with Merck & Co., Inc., Kenilworth, N.J., USA. In addition, a number of investigator-sponsored trials are underway, including a trial to investigate BGB324 with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA in advanced melanoma, as well as a trial combining BGB324 with docetaxel in advanced NSCLC. BerGenBio is simultaneously developing a companion diagnostic test to identify patient subpopulations most likely to benefit from treatment with BGB324. This will facilitate more efficient registration trials and support a precision medicine based commercialization strategy. The Company is also developing a diversified pre-clinical pipeline of drug candidates, including BGB149, an anti-AXL monoclonal antibody.  For further information, please visit: www.bergenbio.com  KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Roche-Genentech. TAFLINAR® is a registered trademark of Novartis International AG and MEKINIST® is a registered trademark of GSK plc. - Ends - Contacts Richard Godfrey CEO, BerGenBio ASA +47 917 86 304 Tom Henrik Sundby Finance Director, BerGenBio ASA tom.sundby@bergenbio.com +47 477 54 415 Media Relations David Dible, Mark Swallow, Marine Perrier Citigate Dewe Rogerson bergenbio@citigatedewerogerson.com  +44 207 638 9571 Forward looking statements  This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements  This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Capio continues to invest in digital healthcare

Capio and Doctrin are collaborating since late 2016. During fall this year, implementation of the new digital tools “Better Visits” and “Online Consultations” (Läkarbesök Online) started in Capio’s primary care operations in Sweden. Both services are based on an extensive medical algorithm, which captures the patient’s medical history in a structured way. The patient is provided healthcare where she or he is, when the need occurs. In addition, the tools support medical quality as the algorithm contributes to more precise diagnoses. For doctors and nurses, the tools support the daily work and contribute to make healthcare available to more patients as the time for e.g. a doctor consultation is shortened. The roll-out to Capio’s 200,000 listed patients in the Skåne region is completed, and work to make the services available to patients in Stockholm has now been initiated. From spring 2018, all of the 750,000 patients listed with one of Capio’s 83 primary care centers will have access to “Better Visits” and “Online Consultations”. In addition, “Online Consultations” will be available to all Swedish inhabitants.  “The collaboration with Doctrin is one of our most important initiatives to improve healthcare provision to our patients through the unique combination of digital services and the physical healthcare provided by Capio”, says Thomas Berglund, President and CEO.  Capio has previously invested MSEK 13 in Doctrin and following the new share issue today, the Group’s total investment is MSEK 62. The minority share is not expected to have any significant financial impact for the Group in 2017 or 2018. Doctrin AB was founded in 2016 and has 29 employees. The company’s registered office is in Stockholm, Sweden. The CEO is Magnus Liungman. For information, please contact:Thomas Berglund, President and CEOTelephone: +46 733 88 86 00 Kristina Ekeblad, IR managerTelephone: +46 708 31 19 40

Sweco expands in Belgium

"I am pleased to welcome HaskoningDHV Belgium to Sweco. Sweco has a very solid base in Belgium. We have an efficient organisation and are continuously growing. The experts from HaskoningDHV Belgium are a perfect match for our multidisciplinary teams, which ensures a smooth continuation for current projects. By joining forces, we will be planning and designing the communities and cities of the future,” says Tomas Carlsson, President and CEO of Sweco. HaskoningDHV Belgium, which operates from Mechelen and Namur, offers services within soil investigations and decontamination, environmental impact assessments and integrated area development. The company’s 36 highly qualified experts will be employed by Sweco as of January 2nd 2018. “We have a clear strategy outlining where we want to operate and ways in which we aim to grow through the efficient delivery of innovative solutions. Based on this, we reviewed our local operations in Belgium. We analysed a number of options to ensure continuity and attractiveness for our current employees and our clients within these services. As Sweco Belgium is focused on growing in these service areas, we are confident that we have found the best possible partner for HaskoningDHV Belgium going forward. Royal HaskoningDHV remains committed to providing the Belgian market with our globally renowned services,” says Erik Oostwegel, CEO Royal HaskoningDHV.   “Sweco is further strengthening its market position with the asset acquisition of HaskoningDHV Belgium. We are growing, and the projects in our portfolio will make ideal use of HaskoningDHV Belgium’s expertise. We have a dedicated integration team to ensure an efficient and fast integration period. Our focus over the next few months will be to integrate all new employees and to ensure continuity in all of our projects," says Erwin Malcorps, Managing Director of Sweco Belgium.

NetEnt signs distribution agreement with IGT for Norsk Tipping

Earlier this year, NetEnt participated as a supplier to IGT in the competitive procurement process of Norsk Tipping for the delivery of online casino content. Norsk Tipping is Norway's state lottery operator and a World Lottery Association (WLA) member. Following a successful tender process, IGT announced in February of this year that it had won a contract with Norsk Tipping to provide online casino games. For more information, see news release: IGT Wins Contracts With Norsk Tipping To Provide Interactive Casino And Instant Win Game Libraries And Customized Games Subsequent to the contract win, NetEnt and IGT have signed an agreement for the supply of online casino games to Norsk Tipping. Under the terms of IGT’s contract with Norsk Tipping, NetEnt will make a wide range of its world-leading games available through the IGT Connect™ integration layer to Norway’s state lottery operator. Enrico Bradamante, MD of NetEnt Malta Ltd, commented: “We look forward to providing our popular game portfolio to Norsk Tipping together with IGT through their IGT Connect™ platform. We are proud to serve yet another customer through IGT in the strategically important WLA segment.” For additional information please contact:Enrico Bradamante, MD of NetEnt Malta LtdPhone: +356 79 676 868enrico.bradamante@netent.com Roland Glasfors, Investor Relations, NetEnt AB (publ)Phone +46 760 024 863roland.glasfors@netent.com This information is information that NetEnt AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on December 11th, 2017. About NetEntNetEnt AB (publ) is a leading digital entertainment company, providing premium gaming solutions to the world’s most successful online casino operators. Since its inception in 1996, NetEnt has been a true pioneer in driving the market with thrilling games powered by a cutting-edge platform. NetEnt is committed to helping customers stay ahead of the competition, is listed on NASDAQ Stockholm (NET–B) and employs 900 people in Stockholm, Malta, Kiev, Krakow, Gothenburg, Gibraltar and New Jersey. www.netent.com About Norsk TippingNorsk Tipping is assigned by the government to offer games that create excitement and entertainment within responsible limits, with the profits going to good causes. Norsk Tipping is a government-owned limited company under the direction of the Ministry of Culture. For more information about Norsk Tipping, please visit the website https://www.norsk-tipping.no/selskapet/engelsk About IGTIGT is the global leader in gaming, enabling players to experience their favorite games across all channels and regulated segments, from Gaming Machines and Lotteries to Interactive and Social Gaming.

Catella Wohnen Europa investment fund acquires 215 residential units in Germany and Netherlands

“While the structure of each of the properties has evolved over time, the buildings have been brought up to modern standards. This makes them a perfect fit for the long-term focus of our portfolio. In addition, we had already acquired a residential property at the Den Bosch location in 2016, with rentals per square metre almost EUR 2 higher than those for the most recently acquired comparable residential units,” says Benjamin Rüther, Deputy Fund Manager at Catella. Lübeck – historically evolved location close to the city centre Built in 1946, this property is located in the St. Lorenz Nord district, close to Lübeck’s city centre. Most of the 149 residential units, with total leasable space of 7,336 square metres, have been renovated in recent years. The average apartment measures around 50 square metres, exactly the size for which there is strong demand at present. The immediate surroundings benefit from generously proportioned green spaces between buildings as well as an organically grown residential area with schools, day-care facilities for children, an indoor swimming pool, a specialist shopping centre and several supermarkets. The purchase price is EUR 15 million. Den Bosch – living by the water The residential complex in Den Bosch, the capital of the province of North Brabant, was built in 1975 and measures around 3,700 square metres. The property has 66 apartments and 61 outside car parking spaces. Originally used as a tax consultancy office, the building was converted into apartments with high-quality finishes and fittings in 2016. The apartment sizes range between 25 and 76 square metres. Prins Hendrikpark, a popular local recreation facility with a petting zoo and expanses of water, is located in the immediate vicinity of the property. The city centre is around 2 km away. The purchase price is around EUR 12.2 million. Den Bosch is very centrally located in the Netherlands and has excellent rail and road links. The size of the population is expected to increase from its current 165,000 in the next few years. The Catella Wohnen Europa investment fund is a German open-end mutual real estate fund for (semi-) professional and wealthy private investors wishing to invest at least EUR 500,000. Launched in February 2016, the fund had already accumulated real estate assets under management of more than EUR 415 million by the end of October 2017. It invests in selected European core markets, such as Germany, France, the Netherlands and Scandinavia. More information:Michael Keune  Managing Director +49 152 388 48 391  michael.keune@catella-investment.com    Catella is a leading specialist in property investments, fund management and banking, with operations in 13 European countries. The group has sales of approximately EUR 200 million and manages assets of approximately EUR 17 billion. Catella is listed on Nasdaq Stockholm in the Mid Cap segment. Read more at catella.com .1/1 

The diabetes vaccine Diamyd® shows positive results

"The results seen in DIAGNODE-1 are gratifying, now that all twelve patients have been followed for 6 months," says Johnny Ludvigsson, Professor at Linköping University and Sponsor of the trial. “It is therefore with enthusiasm that we start DIAGNODE-2, where we have now screened our first patient. It is important to preserve the endogenouss insulin production that remains in newly diagnosed type 1 diabetes patients as even a small amount simplifies life with diabetes, decreases the number of hypoglycemias and leads to fewer long-term complications.”  In the report of the open-label pilot trial DIAGNODE-1, where the diabetes vaccine Diamyd® is given directly into the lymph node, results are now presented for all twelve patients that have been followed for 6 months. No serious adverse events have been reported in the trial, and positive effects are seen on the disease progression. At 6 months, the endogenous insulin producing ability is virtually unchanged. On average, insulin production (measured as stimulated C-peptide, AUC) decreased by 1.7% (compared to expected 15%) while at the same time, patients have on average lower (-22%) long-term blood sugar (HbA1c) and use less insulin (-10%) than at the start of trial. Previously reported preliminary 15-month results for six participants show that the endogenous insulin-producing ability has decreased only by 10.8% (compared to expected 35%), and long-term blood sugar and insulin dose have decreased by 31% and 39% respectively. The treatment also provides a desired immunological response. "DIAGNODE-2, which we have now started, will be very exciting and with participating clinics from Sweden, the Czech Republic and Spain, we will work together for effective patient recruitment," says Ulf Hannelius, CEO of Diamyd Medical. About the disease progression in Type 1 diabetesThe results now available should be viewed in perspective as to how the disease progression usually appears in newly diagnosed type 1 diabetes patients. Type 1 diabetes is an autoimmune disease, which means that the beta cells, the cells in the pancreas that form insulin, are broken down by the immune system. The decreasing insulin production leads to higher blood sugar levels and the patient becomes dependent on externally supplied insulin to survive. Based on data from Diamyd Medical's own studies and other published studies in type 1 diabetes, a patient in the same age group as the participants in DIAGNODE-1 looses approximately 15% of his/her own insulin-producing ability (C-peptide AUC) in the first 6 months and 35% by 15 months. Long-term blood sugar and insulin doses usually remain unchanged or slightly elevated at 6 months and by 15 months the negative disease progression continues, with further elevated blood glucose levels requiring higher insulin doses, which in turn increases the risk of both short-term and long-term complications.  About DIAGNODE-1DIAGNODE-1 is an open label pilot trial, comprising a total of twelve patients between the ages of 12 and 30 with type 1 diabetes, where the diabetes vaccine Diamyd® is administered three times, one month apart, in a low (4µg) dose directly into the lymph node. The treatment is combined with oral vitamin D. Twelve patients have been followed for 6 months and out of these six have been followed for 15 months from inclusion. About DIAGNODE-2DIAGNODE-2 is a follow-up on DIAGNODE-1, where preliminary results show a positive clinical progression and desired immunological response as the diabetes vaccine Diamyd® is given directly into the lymph node. DIAGNODE-2 is a double-blind randomized trial encompassing approximately 80 patients from Sweden, the Czech Republic and Spain, aged 12–24 years that have recently been diagnosed with type 1 diabetes. The patients will be followed for 15 months with the aim to evaluate the remaining insulin producing capacity. Coordinating Investigator is Professor Johnny Ludvigsson at Linköping University. Diamyd Medical is the Sponsor of the trial. About Diamyd MedicalDiamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology. Diamyd Medical develops the diabetes vaccine Diamyd®, for antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Diamyd® has demonstrated good safety in studies of more than 1,000 patients as well as effect in some pre-specified subgroups. Besides the Company’s own European Phase-II trial DIAGNODE-2, where the diabetes vaccine is administered directly into the lymph node, there are four investigator initiated clinical trials ongoing with Diamyd®. Diamyd Medical also develops Remygen®, a proprietary GMP manufactured oral GABA-based study drug. An investigator initiated placebo controlled trial with GABA and Diamyd® in patients recently diagnosed with type 1 diabetes is ongoing at the University of Alabama at Birmingham. Exclusive licenses for GABA and positive allosteric modulators of GABA receptors for the treatment of diabetes and inflammatory diseases constitutes alongside with the diabetes vaccine Diamyd® and Remygen® key assets. Diamyd Medical is also one of the major shareholders in the stem cell company NextCell Pharma AB and has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA. Diamyd Medical’s B-share is traded on Nasdaq First North under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

Change in number of shares in BrainCool AB (publ)

The number of convertible notes converted on December 11, 2017, was 30. The number of convertible notes remaining under the first Tranche for future conversion is 170. The number shares and the number of votes before the conversion was 33 884 292. Through this conversion, and once the shares from the conversion will be registered at Bolagsverket, the number of shares and the number of votes shall have increased by 385 109. The total number of shares and total number of votes after this conversion and once the shares have been registered at Bolagsverket will amount to 34 269 401. For terms and conditions of the convertible notes, please visit: http://www.braincool.se/investor-relations-2/  For more information   Martin Waleij - CEO                                                       +46 - 733 -93 70 76                                                                              E-mail: martin.waleij@braincool.se                                    About BrainCool AB (publ)  BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management.BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on AktieTorget.  This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on December 11, 2017.

Panion’s epilepsy product classified as MUMS in EU for dogs and cats

The MUMS status is granted to assist applicants that intends to develop and submit applications for products for limited markets in order to stimulate development of new medicines. The measures made available by EMA for MUMS-products range from administrative assistance, reduced data requirements, and if the product is for a food-producing species, also fee reductions. Panion’s product is for non-food-producing species, but we already have other financial incentives from EMA based on our status as SME organization (Small and Medium-sized Enterprise). The MUMS classification covers all aspects of applications from early scientific advice to marketing authorisation. Unlike the MUMS-status that was granted to our product by US FDA earlier in 2017, there is no market exclusivity for MUMS-products in EU. For Panion, the most important asset of the classification is that we may now refer to the guidelines on reduced data requirements for veterinary medicinal products classified as MUMS. This has the potential to save time and costs, although the application of these reduced data requirements depends on the individual product and the degree of novelty. The classification was announced on the 8.th of December at 17.50; it is valid for five years and may be renewed. This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR).  This information was submitted by Panion's CEO, Anja E. H. Holm, for publication on December 11, 2017, 8:55 CET. 

2018 hot consumer trends: technology turns human

Exploring the future from an early adopter user perspective, Ericsson (NASDAQ: ERIC) ConsumerLab presents the seventh edition of its annual trend report, The 10 Hot Consumer Trends for 2018 and beyond . The report points to a paradigm shift as consumers expect digital technology to increasingly operate on human terms. Body language, facial expression and intonation will augment voice and touch to control consumer interaction with tech devices, easing adaption in an ever-increasing pace of technological change. These are the 10 trends for 2018 and beyond: 1. Your Body is the User Interface: More than half of current users of intelligent voice assistants believe that we will use body language, expression, intonation and touch to interact with tech devices as if they were fellow humans. Some 2 in 3 think this will happen within a mere 3 years. 2. Augmented Hearing: 63 percent of consumers would like earphones that translate languages in real time. 52 percent want to block out a family member’s snoring. 3. Eternal Newbies: 30 percent say new technology makes it hard to keep their skills up to date. But it also makes us instant experts. 46 percent say the internet allows them to learn and forget skills faster than ever. 4. Social Broadcasting: Social media is being overrun by traditional broadcasters. But half of consumers say AI would be useful to check facts posted on social networks. 5. Intelligent Ads: Advertisements may become too smart for their own good. More than half of augmented reality (AR)/virtual reality (VR) users think ads will become so realistic they will eventually replace the products themselves. 6. Uncanny Communication: 50 percent think not being able to tell the difference between human and machine would spook them out. 40 percent would also be spooked by a smartphone that reacts to their mood. 7. Leisure Society: 32 percent of students and working people do not think they need a job to develop a meaningful life. 40 percent say they would like a robot that works and earns income for them, freeing up leisure time. 8. Your Photo is a Room: Imagine being able to walk into a photo and relive a memory. 3 out of 4 believe that in only 5 years they will use virtual reality to walk around in smartphone photos. 9. Streets in the Air: City streets may be choked with traffic but the skies remain free. 39 percent think their city needs a road network for drones and flying vehicles. But almost as many worry that a drone would drop on their head.10. The Charged Future: The connected world will require mobile power. More than 80 percent believe that in only 5 years we will have long-lasting batteries that will put an end to charging concerns. Michael Björn, Head of Research, Ericsson ConsumerLab, says: "We are entering a future where devices neither have buttons and switches nor need to be controlled digitally via your smartphone. In fact, this may be a necessary change, as it would be difficult for people to learn a new user interface for every device that gets connected to the Internet of Things. “Today, you have to know all the intricacies of the devices you use. But in the future, the devices will know you instead. For this to become a reality, devices must be able to relay complex human interaction data to cloud-based processing, and respond intuitively within milliseconds, increasing requirements on next generation connectivity.” The insights in the 10 Hot Consumer Trends for 2018 report are based on Ericsson ConsumerLab’s global research activities over more than 22 years, and draw on data from an online survey of advanced internet users in 10 influential cities across the world, performed in October 2017. Although the study only represents 30 million citizens, their early adopter profile makes them important to understand when exploring future trends. NOTES TO EDITORS Listen to a podcast with the report’s authors  For media kits, backgrounders and high-resolution photos, please visit www.ericsson.com/press FOLLOW US: www.twitter.com/ericssonwww.facebook.com/ericssonwww.linkedin.com/company/ericssonwww.youtube.com/ericsson MORE INFORMATION AT: News Center  media.relations@ericsson.com(+46 10 719 69 92) investor.relations@ericsson.com(+46 10 719 00 00) Ericsson is a world leader in communications technology and services with headquarters in Stockholm, Sweden. Our organization consists of more than 111,000 experts who provide customers in 180 countries with innovative solutions and services. Together we are building a more connected future where anyone and any industry is empowered to reach their full potential. Net sales in 2016 were SEK 222.6 billion (USD 24.5 billion). The Ericsson stock is listed on Nasdaq Stockholm and on NASDAQ in New York. Read more on www.ericsson.com.

Singtel, Ericsson reach Gigabit speeds in LAA trial

Conducted in a Singtel laboratory, the trial delivered speeds that breached the 1 Gbps barrier by combining several key LTE technologies including 256 QAM, 4x4 MIMO, and aggregating two licensed and three unlicensed spectrum bands on a TM500 Test System device[1] .   Mark Chong, Singtel’s Group Chief Technology Officer says: “We are very encouraged by this breakthrough in peak speeds. In Singapore, a large percentage of mobile traffic is generated indoors with more mobile customers browsing the web, streaming video and accessing cloud applications on the go. We are now in a position to deploy LAA technology to boost our LTE mobile capacity to meet increasing traffic demand. This will allow us to deliver a faster and more reliable mobile connectivity experience even during peak periods.”  The unique 12-layered LAA configuration used in the trial will provide 2 to 3 times faster than prevailing peak LTE speeds, resulting in enhanced user experience, especially in high traffic indoor environments such as shopping malls.  Following this successful trial, Singtel will explore the feasibility to deploy the technology on Singtel’s network.   Martin Wiktorin, Head for Ericsson Singapore, Brunei & the Philippines, says: “Licensed Assisted Access took wireless technology to a whole new level, delivering the increased capacity and faster speeds that operators demand as they evolve their networks. This trial is a significant milestone in the use of LAA, pushing the limits of Gigabit LTE in a unique configuration of advanced technologies.” This latest breakthrough extends the partnership of Singtel and Ericsson  in 4.5G LTE and trialling 5G in Singapore. Earlier this year, high download speeds of up to 800Mbps were achieved on Singtel’s high-performance LTE network by deploying 256 QAM downlink, 4x4 MIMO and triple carrier aggregation techniques. In October 2017, the partners jointly established a 5G Centre of Excellence to facilitate 5G development in Singapore. Singtel’s 4.5G LTE network offers Singapore’s fastest and widest mobile data speeds at 500Mbps nationwide. ### NOTES TO EDITORS About Singtel  Singtel is Asia's leading communications technology group, providing a portfolio of services from next-generation communication, technology services to infotainment to both consumers and businesses. For consumers, Singtel delivers a complete and integrated suite of services, including mobile, broadband and TV. For businesses, Singtel offers a complementary array of workforce mobility solutions, data hosting, cloud, network infrastructure, analytics and cyber-security capabilities. The Group has presence in Asia, Australia and Africa and reaches about 670 million mobile customers in 22 countries. Its infrastructure and technology services for businesses span 21 countries, with more than 428 direct points of presence in 362 cities. For more information, visit www.singtel.com  Follow us on Twitter at www.twitter.com/SingtelNews Media Contact:   Low Mei Yen Manager Group Strategic Communications and Brand Tel: +65 6838 2033 HP: +65 8799 0233 Email: lowmeiyen@singtel.com For media kits, backgrounders and high-resolution photos, please visit www.ericsson.com/press FOLLOW US: www.twitter.com/ericssonwww.facebook.com/ericssonwww.linkedin.com/company/ericsson www.youtube.com/ericsson   MORE INFORMATION AT: News Center  media.relations@ericsson.com(+46 10 719 69 92) investor.relations@ericsson.com(+46 10 719 00 00) Ericsson is a world leader in communications technology and services with headquarters in Stockholm, Sweden. Our organization consists of more than 111,000 experts who provide customers in 180 countries with innovative solutions and services. Together we are building a more connected future where anyone and any industry is empowered to reach their full potential. Net sales in 2016 were SEK 222.6 billion (USD 24.5 billion). The Ericsson stock is listed on Nasdaq Stockholm and on NASDAQ in New York. Read more on www.ericsson.com. ---------------------------------------------------------------------- [1]  In the trial, four layers with 4X4 MIMO on licensed spectrum were used, as well as 2 layers on a second licensed band, and six layers with LAA (2 layers X 3 unlicensed bands). The Ericsson Radio System hardware used included Radio 2203 for the licensed spectrum and Radio 2205 for the LAA (unlicensed spectrum). All radios were connected to a single Baseband 5216. Test device supplied by Cobham Wireless and Stellent Networks Pte Ltd. 

Eurocine Vaccines Challenges the Flu

“The issued patent in the US earlier this year proves the success of our patent strategy. We now hold at least one granted patent from each of our patent applications, whereby the value of our technology is well secured by our intellectual property rights. Based on that, we can now both take the next step in development and also review our portfolio strategy”, says CEO Dr. Hans Arwidsson. The next study - A strategic move Both the elderly and young children[2]  lack the capability of the immune system found in young adults, why the need of a vaccine adjuvant to stimulate protection against disease is often necessary. Therefore, designing the next study to include elderly is a strategic choice. “While engaging more adults in our trials is a necessity before we can perform studies among younger children, the choice of elderly in our next phase adds value both by gaining more knowledge of the adjuvant effects in weaker immune systems and also by opening an additional market segment without losing focus on our vision”, says CSO Dr. Anna‑Karin Maltais. Extended portfolio of nasal vaccines At the same time, the technology of nasal vaccination can be applied to many more fields, providing advantages as great convenience for the patients, with needle free administration, reduced cost of administration and double protection with antibodies both in the mucosa and blood. Eurocine Vaccines will therefore continue to evaluate a broadening of its product portfolio both together with partners and stand-alone. ---------------------------------------------------------------------- [2]  See this short video, where CSO Dr. Anna-Karin Maltais explains why children are more vulnerable and how the adenoid, an immunological organ, can be better stimulated; https://youtu.be/n40I81B2hog ! 

Axactor acquires an unsecured non-performing loan (NPL) portfolio in Sweden

Oslo, 11 December 2017 - Axactor Sweden have acquired a fresh unsecured NPL portfolio. The portfolio includes unsecured credit with a total Outstanding Balance (OB) of approximately EUR6 million, across close to 10,000 open accounts of consumer loans and micro-loans. The portfolio allows Axactor Sweden to get invaluable insight into the rapidly expanding micro-finance sector, as well as including the more vanilla consumer loans. "This acquisition demonstrates Axactor's ability to work with new clients in Sweden and build a well-diversified portfolio. We expect further purchases to follow this one in the coming months.", says Fredrik Kessler, Country Manager Axactor Sweden. The investments will be financed by Axactor's available cash and our existing creditfacilities. For additional information, please contact: Endre Rangnes, CEO Axactor Mobile phone: +47 4822 1111 Email: endre.rangnes@axactor.com or Geir Johansen, CFO & Investor Relations, Axactor Mobile phone: +47 4771 0451 Email: geir.johansen@axactor.com www.axactor.com About Axactor Axactor Group specializes in both Debt Collection and Debt Purchasing across several countries, with operations in Italy, Germany, Norway, Sweden and Spain. The company has a Nordic base and an ambitious Pan-European growth strategy, which targets the market for non-performing loans (NPL) in Europe. This market is estimated to be about 1,500 billion euros across Europe providing significant opportunities for Axactor's future expansion. Axactor has approximately 900 employees.

NEWS; Consensus Statement on Perioperative Use of Neuromuscular Monitoring

The reason for developing the consensus statement was based on a series of reports that indicate a low frequency of routine neuromuscular monitoring and a lack of anesthesia practitioner awareness of the high incidence (40%–60%) of residual NMB and its associated morbidity. The expectation of the panel is that successful implementation of these recommendations will improve patient safety, quality of care, and cost-effectiveness. In addition, it is the aim of the panel to encourage professional societies to develop clinical guidelines for perioperative neuromuscular monitoring. The consensus Statement recommends that: · Whenever a neuromuscular blocker is administered, neuromuscular function must be monitored by observing the evoked muscular response to peripheral nerve stimulation. · Ideally, monitoring should be done at the hand muscles (not the facial muscles) with a quantitative (objective) monitor. · Objective monitoring is the only method of assuring satisfactory recovery of NMB and patient safety. · Subjective tests of NMB are not predictive of adequate neuromuscular recovery and are notsensitive to the presence of residual neuromuscular weakness; their use should be abandoned in favor of objective monitoring · Professional organizations should develop practice standards and guidelines detailing how best tomonitor and manage perioperative administration The panel concludes that EMG devices offer advantages over other categories of monitoring devices, but that currently, there are no commercially available EMG monitors on the market.   Lena Söderström, CEO at Senzime states, "This consensus statement clearly outlines the patient safety problems due to residual neuromuscular block. Our EMG-based monitor, the TetraGraph, will be launched shortly, contributing to enhanced patient safety.”    The International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to advance and support scientific research and education related to anesthesia, and to improve patient care through basic research. The IARS contributes over $1 million annually to fund anesthesia research; provides a forum for anesthesiology leaders to share information and ideas; maintains a worldwide membership of more than 12,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia-related practice and publishes the monthly Anesthesia & Analgesia journal in print and online as well as the clinical companion journal A&A Case Reports, published semi-monthly.  For further information, please contact: Lena Söderström, CEO of Senzime AB Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com TO THE EDITORS About Senzime Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com 

NeuroVive reports promising progress in its clinical project for genetic mitochondrial diseases, KL1333

The first part of the study has been successful. The pharmacokinetic data was in line with expectations and no adverse safety signals were detected. The study’s remaining higher dose-cohorts have now been approved by the Korean medicinal authority, the Ministry of Food and Drug Safety (MFDS). “We are very excited about the progress of the first KL1333 clinical study. Along with the recent positive opinion on European orphan drug designation, it brings us one step closer to initiating our own clinical phase Ib study, and to our ultimate goal of providing a treatment opportunity to patients with different genetic mitochondrial disorders, where there is a high medical need and in most cases no specific treatments available,” commented Magnus Hansson, M.D., Ph.D., Chief Medical Officer and VP of Preclinical and Clinical Development at NeuroVive. The study is a double-blind, placebo-controlled, single-dose, dose-escalation phase I clinical study to investigate the pharmacokinetics, safety and tolerability of KL1333 in healthy volunteers. The first part of the study included dose levels of 25 mg and 50 mg. With both doses having been deemed safe, the MFDS has approved dose escalation and an updated study design. A multiple-dose, phase Ib study, sponsored by NeuroVive, is planned to be initiated in Europe and/or the U.S. in 2018. “The results from the first part of the study are positive and the approval from the MFDS is of crucial importance for KL1333 and the continuation of its global development program. In close collaboration with our partner NeuroVive, we have a great possibility to develop KL1333 into a novel treatment opportunity for patients with genetic mitochondrial disorders, such as MELAS,” said Soo-Hyun Lew, M.D. Executive Director of Development at Yungjin Pharm. This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 11:00 a.m. CET on 11 December 2017. For more information please contact: Daniel Schale, Director of Communications, NeuroVive +46 (0)46-275 62 21, ir@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) info@neurovive.com, www.neurovive.com About NeuroVive  NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). About KL1333 KL1333 is a potent modulator of the cellular levels of NAD+, a central coenzyme in the cell’s energy metabolism. KL1333 has in preclinical models been demonstrated to increase mitochondrial energy output, reduce lactate accumulation, diminish the formation of free radicals, and to have long-term beneficial effects on energy metabolism such as the formation of new mitochondria. It is in clinical development stage intended to document the use for chronic oral treatment in primary genetic mitochondrial disorders such as MELAS, KSS, CPEO, PEO, Pearson and MERRF. Its mode of action is complementary to that of NVP015, which is intended to alleviate acute episodes of energy crises in genetic mitochondrial disorders with dysfunction in complex I and to NVP025, intended to protect the mitochondria in skeletal muscle from dysfunctional calcium handling and consequential muscle wasting. About Yungjin Pharm Yungjin Pharm Co. Ltd., established in 1952, has been playing a major role as a forerunner in the Korean pharmaceutical industry for half a century. With the inspiring mission statement, "To relieve the suffering of mankind from diseases with our innovative, effective and safe pharmaceutical products", they have shown a successful contribution not only within Korea, but also through global expansion. As a result, they have received a total of 25 awards including the President Award for Superior Product Development, the Prime Minister Award, Industry Award and many more. These accomplishments demonstrate their sustainability and commitment to the development of innovative products and business excellence in both overseas and domestic segments. The company is listed on the South Korean stock market, KOSPI (KRX 003520).

Atea Denmark attains highest ISO anti-bribery certification

To attain the certification, Atea Denmark has worked in a structured and continuous manner for over two years to enhance and document its anti-bribery systems. This has included an evaluation of when the company is at risk of non-compliance with legislation, internal policies and guidelines. Furthermore, Atea Denmark has detailed its business processes, procedures and work culture related to sales to both the public and private sectors. The anti-bribery work was initiated in the summer of 2015 after allegations that former Atea Denmark employees were involved in bribery. The case is currently being handled by the court. “Since 2015, we have conducted an extensive self-cleaning process under EU legislation, and have enhanced our compliance programs to prevent bribery, corruption and other forms of unethical business behavior,” commented Morten Felding, Managing Director of Atea Denmark. “Now we are proud of being the first organization in Denmark to have attained the ISO 37001 anti-bribery systems certification. With this certification, we aim to demonstrate to all of our company’s stakeholders, including customers and partners, our commitment and internal practices toward the prevention of bribery.” To attain the ISO 37001 certification, Atea Denmark has completed an audit conducted by Bureau Veritas Certification. For further information, please contact: Steinar Sønsteby, CEO Atea ASA, mobile (+47) 930 55 655 About Atea Atea is the leading supplier of IT infrastructure and system integration in the Nordic and Baltic regions with 6,900 employees. Atea is present in 86 cities in Norway, Sweden, Denmark, Finland, Lithuania, Latvia and Estonia. Atea delivers IT products from leading vendors and assists its customers with specialist competencies within IT infrastructure services. Atea had revenue of approximately NOK 31 billion in 2016 and is listed on Oslo Stock Exchange. www.atea.com

ExpreS2ion and Intravacc enter collaboration agreement

Memorandum of Understanding ExpreS2ion, a fully owned subsidiary of ExpreS2ion Biotech Holding AB, and Intravacc, an experienced vaccine R&D institute, have signed a Memorandum of Understanding (MoU). The MoU enables ExpreS2ion to service customers and collaboration partners across the full value chain of development of vaccines, from discovery up till GMP production and clinical trials. Under the agreement, Intravacc will serve as a preferred GMP partner for ExpreS2ion. Serving as a reference for expanded customer outreach, the MoU contains no financial exchange between ExpreS2ion and Intravacc. However, it expands the commercial opportunities in the vaccine field for both organisations. ExpreS2ion CEO Dr. Steen Klysner comments  “We are very satisfied to expand ExpreS2ion’s capabilities into the manufacturing of vaccines through the establishment of a preferred partnership with Intravacc. This strategic alliance increases ExpreS2ion’s service offerings and continues our repositioning into a one-stop solution provider for vaccine developing SMEs and Pharma companies.” Intravacc CEO Thijs Veerman Msc comments “We are proud to serve as a preferred GMP partner for ExpreS2ion and its clientele. Intravacc offers one-stop solutions for GMP production and clinical development and has a strong track record in the technology transfer of vaccine products and knowhow to our partners. Our experience with the development and successful technology transfer of vaccines such as Haemophilus influenzae b and Sabin inactivated Polio vaccine to vaccine manufacturers has paved the way for a fast and product oriented route to market.” About Intravacc   Intravacc, based in Bilthoven, the Netherlands, is an established R&D organisation with more than 100 years’ experience in optimisation of vaccines, vaccine processes and vaccine technologies. Intravacc has state-of-the-art production facilities and its aim is to substantially reduce development risks and costs of new vaccines in order to contribute to global health and equity in access to vaccines worldwide. More information at www.intravacc.nl. For further information about Intravacc, please contact: Thijs Veerman Msc, CEO Telephone: +31 30 7920445 E-mail: thijs.veerman@intravacc.nl  Certified Adviser  Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.

The Nomination Committee’s proposal for Board of Directors of Indutrade AB for the 2018 Annual General Meeting

The Nomination Committee proposes that Katarina Martinson be elected as Chairman of the Board at the 2018 Annual General Meeting. The Committee also proposes the re-election of Board members Susanna Campbell, Bengt Kjell, Ulf Lundahl, Krister Mellvé, Lars Pettersson and Bo Annvik. Anders Jernhall is proposed as new Board member. The current Chairman, Fredrik Lundberg, has declined re-election. The timing for handing over the Chairmanship is deemed appropriate. Katarina Martinson has extensive knowledge of the company, which will ensure the continuity of the Board’s work. Fredrik Lundberg has expressed a wish to step down from one of his assignments, as an adaptation to the ESMA and EBA Guidelines for assessing the suitability of members of the management body, which will take effect on 30 June 2018. The Guidelines set out the maximum number of assignments that a Board member of a major banking company may undertake. Fredrik Lundberg is Vice Chairman of Handelsbanken. Katarina Martinson was born in 1981, holds a B.Sc. Econ and has been a member of Indutrade’s Board since 2015. Katarina is a Board member of the listed companies L E Lundbergföretagen AB and Husqvarna Group. She is also a main investor and Board member of Fidelio Capital. Anders Jernhall was born in 1970 and holds a B.Sc. Econ. He is Executive Vice President and CFO of Holmen AB. The Nomination Committee’s proposal entails that the number of Board members (eight) will remain unchanged during the forthcoming term of office. Indutrade’s Annual General Meeting will be held on 26 April 2018. Stockholm, 11 December 2017 The Nomination Committee

Victoria Park and Trianon acquire housing units in Malmö for SEK 795 M

Victoria Park AB and Fastighets AB Trianon have signed an agreement to acquire a property portfolio of 722 flats and a small number of commercial premises, with a total lettable area of approximately 47,700 square metres. The properties are located in Lindängen, Malmö, and the acquisition will take place for an underlying property value of SEK 795 M. The seller is Willhem and possession is due to be transferred on 1 March 2018. “It is gratifying to carry out this transaction together with Trianon. We already have a significant share of our total portfolio in Malmö, which provides us with efficient and scalable property management,” says Victoria Park’s CEO Peter Strand. The portfolio, which has been partly renovated in recent years, is fully leased. The acquisition will take place in company form and is based on an underlying property value of SEK 795 M, where the preliminary purchase consideration for shares totals approximately SEK 551 M, of which Victoria Park will pay about SEK 231 M and Trianon about SEK 320 M. Both Victoria Park and Trianon will finance the acquisition with existing cash and by raising new loans, in accordance with company policies. Possession is scheduled for 1 March 2018 when the purchase consideration is to be paid. The acquired company will, after possession, be divided and Victoria Park and Trianon will consolidate their respective parts. Victoria Park will be a long-term owner of almost 300 flats and Trianon of just over 400 flats. The property value is broken down into SEK 462 M for Trianon’s share, corresponding to approximately SEK 16,900 per square metre, with an average residential rent of about SEK 1,350 per square metre. Victoria Park’s share has a property value of SEK 333 M, corresponding to approximately SEK 16,400 per square metre, with an average residential rent of about SEK 1,200 per square metre. The division is expected to be complete by 31 March 2018. “The properties are located close to our existing property portfolio at Lindängen in Malmö, and we view this as a strategic opportunity to increase our presence in the area and will offer further efficiencies in our property management. We are delighted to conduct this acquisition together with Victoria Park. It will strengthen the continued development process in the area,” says Trianon’s CEO Olof Andersson. For further information, please contactVictoria Park:Peter Strand, CEO, +46 (0)70 588 16 61, peter.strand@victoriapark.seTommy Åstrand, CFO, +46 (0)70 545 59 97, tommy.astrand@victoriapark.seTrianon:Olof Andersson, CEO, +46 (0)40 611 34 97, olof.andersson@trianon.seMari-Louise Hedbys, Deputy CEO, CFO, +46 (0)733 70 75 39, mari-louise.hedbys@trianon.se This constitutes information that Victoria Park AB and Fastighets AB Trianon are legally obliged to publish according to the EU Market Abuse Regulation. The information was issued for publication by Peter Strand and Olof Andersson on 11 December 2017 at 1:15 p.m. Victoria Park AB (publ) is a listed property company, which, through long-term management and social responsibility for more secure housing, creates value in an expanding property portfolio in growth districts in Sweden. Victoria Park's property portfolio amounts to 1,062,000 square metres, comprising more than 13,425 flats, with a market value of SEK 14.6 billion. The shares in Victoria Park are listed for trading on Nasdaq Stockholm Mid Cap. For more information, visit www.victoriapark.se Trianon is an entrepreneurial property company in Malmö. The company was founded in 1973 and has witnessed strong growth in property value, particularly since 2006, through its own management, development and acquisitions. Trianon’s property portfolio comprises 44 properties with 223,000 square metres of leasable area, divided into about 50 percent housing and 50 percent commercial and community service properties. The property portfolio had a market value on 30 September 2017 of approximately SEK 4.6 Bn. The head office is located in Malmö. Trianon’s share is listed on Nasdaq First North Premier, with the ticker symbol TRIAN B. The certified adviser is Avanza, +46 (0)8 4094 21 20. For more information, visit www.trianon.se Victoria Park AB (publ), Box 2, SE-201 20 Malmö, Tel +46 (0)40 16 74 40, Corp. Reg. No 556695-0738, Head Office Malmö, www.victoriapark.se           Fastighets AB Trianon (publ), Stenhuggaregatan 2, SE-211 41 Malmö, Tel +46 (0)40 611 34 00, Corp. Reg. No 556183-0281, Head Office Malmö, www.trianon.se  

The Finnish Competition and Consumer Authority applies for an extension for investigating the merger of Lemminkäinen Corporation and YIT Corporation

LEMMINKÄINEN CORPORATION  STOCK EXCHANGE RELEASE 11 DECEMBER 2017 AT 2:30 P.M. This stock exchange release may not be published or distributed, in whole or in part, directly or indirectly, in or into Canada, Australia, Hong Kong, South Africa, Japan or any other country where such publication or distribution would violate applicable laws or rules or would require additional documents to be completed or registered or require any measure to be undertaken, in addition to the requirements under Finnish law. For further information see "Important notice" below. THE FINNISH COMPETITION AND CONSUMER AUTHORITY APPLIES FOR AN EXTENSION FOR INVESTIGATING THE MERGER OF LEMMINKÄINEN CORPORATION AND YIT CORPORATION The Boards of Directors of Lemminkäinen Corporation (“Lemminkäinen”) and YIT Corporation ("YIT") have on 19 June 2017 agreed on combining the companies through a statutory absorption merger under the Finnish Companies Act. Pursuant to the merger plan, Lemminkäinen shall be merged into YIT so that all assets and liabilities of Lemminkäinen shall be transferred without a liquidation procedure to YIT, and Lemminkäinen will be dissolved. The Extraordinary General Meetings of Lemminkäinen and YIT have on 12 September 2017 approved the merger. The completion of the merger is still subject to, inter alia, merger control approval from the Finnish Competition and Consumer Authority (“FCCA”). The FCCA’s investigation on the merger of Lemminkäinen and YIT is still pending and, in order to handle the matter, the FCCA has today applied for an extension from the Finnish Market Court until 26 January 2018. Provided that the Finnish Market Court will grant the applied extension, the completion of the merger will likely be delayed so that the completion will be possible on 1 February 2018, at the earliest. Additional information will be published after the Finnish Market Court has given its decision on the matter.   LEMMINKÄINEN CORPORATIONCorporate Communications ADDITIONAL INFORMATION:Johan Nybergh, General CounselTel. +358 2071 53304johan.nybergh@lemminkainen.com DISTRIBUTION:Nasdaq Helsinki LtdKey mediawww.lemminkainen.com Lemminkäinen is an expert in complex infrastructure construction and building construction in Northern Europe and one of the largest paving companies in its market. Together with our customers and 4,700 professionals we employ, we build a sustainable society. In 2016, our net sales were EUR 1.7 billion. Lemminkäinen Corporation’s share is quoted on Nasdaq Helsinki Ltd. www.lemminkainen.com IMPORTANT NOTICE The distribution of this release may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restrictions. The information contained herein is not for publication or distribution, directly or indirectly, in or into Canada, Australia, Hong Kong, South Africa or Japan. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. This release is not directed to, and is not intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. No part of this release, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. The information contained in this release has not been independently verified. No representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. Neither YIT nor Lemminkäinen, nor any of their respective affiliates, advisors or representatives or any other person, shall have any liability whatsoever (in negligence or otherwise) for any loss however arising from any use of this release or its contents or otherwise arising in connection with this release. Each person must rely on their own examination and analysis of YIT, Lemminkäinen, their respective subsidiaries, their respective securities and the merger, including the merits and risks involved. Notice to Lemminkäinen Shareholders in the United States The YIT shares to be issued in connection with the merger have not been registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and are being issued in reliance on the exemption from registration set forth in Rule 802 under the Securities Act.  YIT and Lemminkäinen are Finnish companies and the issuance of YIT shares will be subject to procedural and disclosure requirements in Finland that may be different from those of the United States. Any financial statements or other financial information included in this release may have been prepared in accordance with non-U.S. accounting standards that may not be comparable to the financial statements of U.S. companies or companies whose financial statements are prepared in accordance with generally accepted accounting principles in the United States. It may be difficult for U.S. shareholders of Lemminkäinen to enforce their rights and any claims they may have arising under U.S. federal securities laws in connection with the merger, since YIT and Lemminkäinen are located in non-U.S. jurisdictions, and some or all of YIT's and Lemminkäinen's officers and directors may be residents of countries other than the United States. As a result, U.S. shareholders of Lemminkäinen may not be able to sue YIT or Lemminkäinen or their respective officers and directors in a court in Finland for violations of U.S. federal securities laws. Further, it may be difficult to compel YIT or Lemminkäinen to subject themselves to the jurisdiction or judgment of a U.S. court. Lemminkäinen’s shareholders should be aware that YIT may purchase Lemminkäinen’s shares otherwise than under the merger, such as in open market or privately negotiated purchases, at any time during the pendency of the proposed merger. Notice to Shareholders in the United Kingdom This release, the merger prospectus and the English language offering circular are for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 43 of the Financial Promotion Order (for example as shareholders in Lemminkäinen entitled to receive the merger consideration shares pursuant to the Finnish Companies Act (21.7.2006/624, as amended)), (iii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iv) are outside the United Kingdom, or (v) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of the merger consideration shares may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). The release, the merger prospectus and the English language offering circular are directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which these documents relate, are available only to relevant persons and will be engaged in only with relevant persons. Notice to Shareholders in the European Economic Area The English language offering circular has been prepared on the basis that any offer of the merger consideration shares in any Member State of the European Economic Area ("EEA") other than offers (the "Permitted Public Offers") which are made prior to the Effective Date (as defined in the English language offering circular), and which are contemplated in the English language offering circular in Finland once the Finnish language merger prospectus has been approved by the competent authority in Finland and published in accordance with the Prospectus Directive, and in respect of which YIT has consented in writing to the use of the English language offering circular, will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of the merger consideration shares. Accordingly any person making or intending to make an offer in that Member State of the merger consideration shares which are the subject of the offer contemplated in the English language offering circular, other than the Permitted Public Offers, may only do so in circumstances in which no obligation arises for YIT to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive, in each case, in relation to such offer. YIT has not authorised, nor does it authorise, the making of any offer (other than Permitted Public Offers) of the merger consideration shares in circumstances in which an obligation arises for YIT to publish or supplement a prospectus for such offer. In relation to each Member State of the EEA, with effect from and including the date on which the Prospectus Directive was implemented in that Member State (the "Relevant Implementation Date") no offer has been made and will not be made (other than a Permitted Public Offer) of the merger consideration shares which are the subject of the offering contemplated by the English language offering circular to the public in that Member State, except that, with effect from and including the Relevant Implementation Date, an offer of such merger consideration shares is made to the public in that Member State: a) to any legal entity which is a qualified investor as defined in the Prospectus Directive; b) to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of YIT for any such offer; or c) in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no offer of the merger consideration shares is made which would require YIT to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. The expression an offer of the merger consideration shares to the public in relation to any merger consideration shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the merger consideration shares to be offered so as to enable an investor to decide to purchase or subscribe to the merger consideration shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State. The expression "Prospectus Directive" means Directive 2003/71/EC (as amended), and includes any relevant implementing measure in the EEA Member State concerned.

Episurf Medical’s 100th Episealer® implant in Germany

Episurf Medical announces that the surgery of the 100th Episealer® implant in Germany will take place in the coming weeks. “There is currently great activity around the Episealer® knee implants in the German market. Several German clinics have initiated marketing activities where they use the Episealer® as a proof of being at the forefront of novel knee cartilage treatments. This is of course of great help for our market acceptance. We would like to thank all the clinics working with us at this early stage, as we jointly work towards helping a large group of patients back to living life“ says Pål Ryfors, CEO of Episurf Medical.  In total, more than 250 patients have been treated with the Episealer® knee implantat. For more  information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.00 CET on 11 December 2017.

UPDATE ON PROPOSED INVESTMENT INTO EMAS OFFSHORE LIMITED AND RESTRUCTURING

1.         Introduction 1.1       The Board of Directors (the “Board”) of EMAS Offshore Limited (the “Company” and together with its subsidiaries, the “Group”) refers to the announcements made on 31 August 2017, 4 September 2017 and 26 September 2017 (“Previous Announcements”).  Unless otherwise defined, terms used in the Previous Announcements shall have the same meanings when used herein. 2.         Update on Investment by the Potential Investors 2.1        It was announced in the Previous Announcement that, inter alia, the Term Sheet may be terminated, and the Restructuring Exercise contemplated may be abandoned, at any time      prior to closing by any of the Potential Investors or the Company, if the Restructuring Exercise     was not under way by or the Scheme application was not filed by 30 October 2017. 2.2       The Board wishes to inform shareholders of the Company that on 9 December 2017 it exercised its right under the Term Sheet to terminate the Term Sheet. Accordingly, the Term Sheet was terminated with effect on 9 December 2017. On the same day, the Company entered into a new binding term            sheet with BTI (“BTI Term Sheet”) in relation to the proposed            cash investment by BTI into the Company as part of the Restructuring Exercise of the Group       (“Investment”). 2.3       The BTI Term Sheet will allow the Group to continue with its Restructuring Exercise to substantially deleverage the Group’s balance sheet by way of, inter alia, schemes of arrangement to be proposed by the Company and certain of its subsidiaries under Section 210 or Section 211I of the Companies Act (Cap.50) of Singapore (“Schemes”) and to strengthen its working capital position by way of the subscription of new shares by BTI and co-investors, if any, to be issued out of the share capital of the Company (“New Shares”). The completion of the Restructuring Exercise and the Investment will enable the Group to continue as a going concern.   3.         Salient Terms of the BTI Term Sheet 3.1        The salient terms of the BTI Term Sheet are set out in the table below: +-----------+------------------------------------------------------------------+|Investment |The aggregate investment amount is US$50 million for the whole and||Amount |complete Restructuring Exercise (“Investment Amount”). |+-----------+------------------------------------------------------------------+|Investment |The subscription of new ordinary shares to be issued out of the || |Company’s capital (“New Shares”) which shall rank pari passu with || |the ordinary shares of the Company in issue and shall be listed || |and quoted on the Oslo Børs and the Singapore Exchange Securities || |Trading Limited (“SGX-ST”).  The Investment may be structured at || |BTI’s option as: (i) a stand-alone investment; (ii) as a || |cornerstone investment for a traditional capital market equity || |raise and/or an investment alongside a co-investor (collectively || |the “Investors”); or (iii) in lieu of the foregoing options, any || |other viable structure, subject to a minimum investment by BTI of || |US$25 million. For the avoidance of doubt, if there is no other co|| |-investor and/or subscriber, BTI will invest the entire Investment|| |Amount. |+-----------+------------------------------------------------------------------+|Share |The Investment Amount will result in the Investors receiving at ||Issuance |least (and in aggregate, if more than one Investor) a majority of || |the enlarged issued share capital of the reorganized Company || |(after the issuance of the New Shares but prior to dilution by the|| |issuance of New Shares underlying the Restructuring Exercise, the || |planned management incentives and subsequent repair issue of the || |Company’s shares pursuant to the listing requirements of the Oslo || |Børs). To ensure business continuity and operations of the EOL || |Group will not be impacted, pending as well as after, the || |completion of the Investment and Restructuring Exercise, it is the|| |intention of the Investors and the Company that key management and|| |support staff of the Group is retained via the planned management || |incentives. |+-----------+------------------------------------------------------------------+|Conditions |The consummation of the transactions contemplated under the Term ||precedent |Sheet is subject to, inter alia, the following main conditions || |precedent: a)    satisfactory completion of due diligence by the || |Investors; b)    satisfactory agreement to final documentation and|| |definitive agreement; c)     no material deterioration of the || |business and financial position and/or prospects of the Group; || |d)    receipt of necessary corporate approvals from the Investors,|| |including but not limited to approval from the Investors’ || |shareholders; e)    requisite approvals for the Restructuring || |Exercise, including the approval of the Company’s shareholders || |having been duly obtained and such approvals not having been || |revoked and the Schemes having been sanctioned by the High Court || |of Singapore; f)      receipt of all necessary governmental and || |regulatory approvals, consents and permits; g)    receipt of || |approval of the Company’s shareholders and/or regulatory approval,|| |if necessary, to waive any subsequent repair issue of the || |Company’s shares that exceeds 3% of the enlarged issued share || |capital of the reorganized Company (after the issuance of the New || |Shares but prior to dilution by the issuance of New Shares || |underlying the Restructuring Exercise and the planned management || |incentives); and h)    any further conditions as deemed necessary || |by the Company and/or the Investors. |+-----------+------------------------------------------------------------------+|Termination|The Term Sheet may be terminated, and the Restructuring Exercise || |contemplated may be abandoned, at any time prior to closing of the|| |Investment: a)    by mutual consent of the Investors and the || |Company; b)    by BTI in writing in the event the Company seeks to|| |vary the terms agreed in the BTI Term Sheet;   c)     by the || |Investors in writing, if the application to convene the creditors’|| |meeting in respect of the Schemes (“Scheme Applications”) are not || |filed by 15 December 2017; d)    by the Investors in writing, if || |there has been a failure to fulfil any of the material commercial || |terms of the BTI Term Sheet, which has prevented or would prevent || |the satisfaction of any condition to the closing of the || |Investment; e)    by the Investors in writing, if the Scheme || |Applications are not heard within 3 months from the date of filing|| |of the Scheme Applications; and f)      by the Investors in || |writing, if the New Shares are not allotted and issued to the || |Investors and/or their nominee(s) within 6 months from the date of|| |filing of the Scheme Applications. |+-----------+------------------------------------------------------------------+ 4.         Update on the Restructuring   4.1       The Company wishes to announce that each of the Singapore Filing Entities, namely the Company, together with its wholly owned subsidiaries, Emas Offshore Pte Ltd and Emas Offshore Services Pte Ltd, made a Scheme Application to the High Court of the Republic of Singapore (“Court”) under Section 210(1) of the Companies Act (Cap.50) of Singapore. 4.2       The Scheme Applications seek, amongst others, the Court’s leave for each of the Singapore Filing Entities to convene their respective creditors’ meeting within four (4) months (or such period as the Court may order) from the date of the order, for the purposes of considering and, if thought fit, approving with or without modification (which modification can be made any time prior to and/or at the creditors’ meeting) the respective Scheme proposed to be made between the Singapore Filing Entities and their creditors pursuant to Section 210(1) of the Companies Act (Cap.50) of Singapore. 4.3       The Scheme Applications will be heard on a date to be fixed by the Court at a pre-trial conference scheduled on 21 December 2017. 5.         General The Company will provide further updates pertaining to the Investment and/or the Restructuring Exercise when there are material developments. Shareholders should note as there is no certainty or assurance as at the date of this announcement that any definitive agreements will be entered into in connection with the Investment and/or the Restructuring Exercise. When in doubt as to the action they should take, shareholders should consult their financial, tax or other advisers. This announcement is subject to disclosure in accordance with section 5-12 of the Norwegian Securities Trading Act. By Order of the Board Lee Kian Soo Director 11 December 2017

Verizon awards 5G contract to Ericsson

Verizon has selected Ericsson (NASDAQ: ERIC) to provide networking equipment for their commercial 5G launch. Verizon will deploy the pre-standard 5G commercial radio network and the 5G Core network in select markets in second half of 2018. The companies are demonstrating continued industry leadership by accelerating the path to 5G . Verizon and Ericsson plan to work together to move the mobile ecosystem towards rapid commercialization of 5G. Ed Chan, SVP Technology Strategy and Planning for Corporate Networking and Technology, Verizon says: “5G will change the way we work, interact, learn and play. Through our work with Ericsson, we are creating a clear roadmap and building a robust ecosystem that will enable us to maximize the potential of 5G.” Fredrik Jejdling, Executive Vice President and Head of Business Area Networks, Ericsson, says: “Our pioneering work with 5G will make US consumers and businesses among the first in the world to benefit from the transformative services of the new technology. It further illustrates how our global 5G portfolio, designed to support 5G NR as standardized in 3GPP, enables first movers in the early commercialization of 5G networks.” During the past year, Ericsson and Verizon have conducted fixed-wireless 5G trials using mmWave spectrum in multiple cities and residential neighborhoods with different geographies and housing densities. This has been a critical step in Verizon’s plan to deploy a first-of-its-kind fixed wireless broadband network. These trials have also been instrumental in understanding 5G technologies and mmWave propagation used in the Verizon 5GTF and the coming 3GPP 5G NR standard. These new technologies are expected to be critical in meeting the increasing connectivity requirements for emerging, mobile and fixed wireless, consumer broadband experiences, such as streaming high-definition video, immersive virtual/augmented reality, and connected cloud computing. NOTES TO EDITORS www.ericsson.com/5g For media kits, backgrounders and high-resolution photos, please visit www.ericsson.com/press FOLLOW US: www.twitter.com/ericssonwww.facebook.com/ericssonwww.linkedin.com/company/ericssonwww.youtube.com/ericsson  MORE INFORMATION AT: News Center  media.relations@ericsson.com(+46 10 719 69 92) investor.relations@ericsson.com(+46 10 719 00 00) Ericsson is a world leader in communications technology and services with headquarters in Stockholm, Sweden. Our organization consists of more than 111,000 experts who provide customers in 180 countries with innovative solutions and services. Together we are building a more connected future where anyone and any industry is empowered to reach their full potential. Net sales in 2016 were SEK 222.6 billion (USD 24.5 billion). The Ericsson stock is listed on Nasdaq Stockholm and on NASDAQ in New York. Read more on www.ericsson.com.

Coor signs new and expanded IFM agreement with Fortum Värme

Coor’s assignment for Fortum Värme covers three geographical regions in Stockholm: south, northwest and the city center, which includes Fortum Värme’s head office. The delivery encompasses 450,000 m2 distributed over five primary facilities, as well as a number of leading-edge plants and pump stations. Coor is responsible for technical property operations, cleaning and work place services including technical security as well as surveillance via receptionists who have also been trained as security guards. ”We’ve had the privilege of working alongside Fortum Värme since 2013. In this period, we’ve developed our services in partnership with Fortum Värme and we’re now looking forward to taking the next step and building an even better delivery on the basis of the new agreement,” commented Mikael Stöhr, President and CEO at Coor. Fortum Värme has emphasized the importance of sustainability in the procurement, as well as the requirement that products used meet the criteria for eco-labeling, but also that Coor, in dialogue with the Labor Market Administration in Stockholm, will review the possibility of engaging people far from the labor market, within the framework of the Fortum assignment. "We have done a solid preparatory work for the procurement and the new agreement has a different design which creates new opportunities for ongoing follow-up and development during the contract period," says Ulrika Magnusson, Facility Management responsible, Fortum Värme. For more information, images etc., please visit www.coor.com or contact:   Mikael Stöhr, President and CEO at Coor +46 10 559 59 35 mikael.stohr@coor.com Sofie Schough, Acting Communication director at Coor +46 10 559 59 83 sofie.schough@coor.com

Loudspring increases ownership in Eagle Filters

Loudspring Oyj Company Release 12.12.2017, 08:30 (EEST) Loudspring is exercising a part of its options in Eagle Filters, and increases its ownership from 28% to 34%. Loudspring has the additional option to increase its ownership further to 40%. Eagle Filters is accumulating more and more verified customer data that proves the economic and environmental benefits of its technology, and Eagle management estimates that the potential for follow-on business within current customer base is high. Eagle Filters enables significant fuel efficiency and therefore CO2 savings for the global energy industry. The company provides high efficiency intake air filtration solutions for gas fired power plants. Utilizing Eagle’s technology in existing gas power plants, energy producers achieve fuel savings in the range of 1-3 MEUR per power plant annually and simultaneously cutting CO2 emissions and urban air pollution. The savings are mainly due to increased fuel efficiency of the turbines because of less fouling of compressor blades when the intake air is efficiently cleaned. Alexander Lidgren, CEO Loudspring comments: “We are extremely proud of the progress Eagle Filters has made working with some of the largest energy companies in the world. This is well in line with our decision to increase ownership in high performers with low additional capital need and the recurring nature of Eagle’s revenues is especially appealing for Loudspring when looking at increasing our ownership.”

Probi signed major agreement for launch of Functional Food product in North America

Probi has signed a major agreement with a Global FMCG-company (fast-moving consumer goods) for their launch of a Functional Food product containing Probi’s bacteria for gut health in North America and potentially other territories. Launch of the product, under a leading brand within its category, is planned for the second half of 2019 in the North American market. The agreement is expected to have significant impact on future revenues and earnings in Probi’s Functional Food business area. In 2016, Probi had net sales of 35 MSEK in the Functional Food business area, corresponding to 8% of total net sales. This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 12 December 2017 at 08.00 CET. FOR FURTHER INFORMATION, CONTACT:Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23, e-mail: peter.nahlstedt@probi.comJörn Andreas, CFO, Probi, tel +46 46 286 89 41, e-mail: jorn.andreas@probi.com (jorn.andreas@probi.com)Niklas Brandt, CIO & Investor relations, Probi, tel +46 46 286 89 26, e-mail: niklas.brandt@probi.com ABOUT PROBIProbi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2016, Probi had net sales of MSEK 444. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at www.probi.se. 

Autoliv concludes strategic review and prepares for spin-off of its Electronics segment

The analyses conducted under the strategic review concluded that the assumptions made at the time of the initial announcement in September 2017 to separate the Company hold true. Through the separation, additional value for shareholders and other stakeholders will be created by the ability to better address two distinct, growing markets with leading product offerings. The key drivers for the separation include: ·The different pace of technology advancement in the two businesses ·Different skill sets of people throughout the organizations (leadership, engineering, sales) ·Different Sales growth rates over the near and long-term with limited customer or operational synergies ·Different market needs driving investments for growth and innovation (RD&E) ·A potentially different shareholder profile due to the timing of returns “With the strategic review concluded we now continue the process with full focus on a successful introduction of our two business segments as stand-alone companies during 2018. We are excited about the strategic opportunities for both our current business segments as separate companies”, said Jan Carlson, Chairman, President and CEO of Autoliv. The spin-off will be effected by a payment of a dividend of the common stock of the new Electronics company on a pro rata basis to the holders of common shares (including through Swedish Depository Receipts) of Autoliv as of a yet to be determined record date. As part of the preparation for the spin-off, the Electronics business is expected to receive a cash injection from Autoliv, with the underlying objective of Autoliv to remain strong investment grade. The intent is for the spin-off to be tax free to stockholders both in the US and Sweden. A Form 10 registration statement for the transaction will be filed with the Securities and Exchange Commission during the first half of 2018. It will include historical financial information for the Electronics business on a stand-alone basis for the fiscal years 2015-2017 and other details regarding the proposed spin-off. After the spin-off, Autoliv’s current Passive Safety segment would continue to operate under the Autoliv name, with continued listings on the New York Stock Exchange and Nasdaq Stockholm. The Electronics business will assume a new company name to be announced at a later stage. It is also expected to be listed in the United States and Sweden. Both companies are to be headquartered in Stockholm, Sweden. Forward looking full year 2018 indications for the stand-alone entities are expected to be given in connection with Autoliv’s Q4 2017 earnings release. The spin-off is expected to be completed during the third quarter of 2018 subject to market, regulatory and certain other conditions, including approval by Autoliv’s board of directors. There can be no assurance regarding the ultimate timing of the spin-off or that the spin-off will ultimately occur. Further updates to the progress of the separation and stock market listing process will be provided in a timely manner. Background Electronics consists of Active Safety Products (automotive radars, cameras with driver assist systems, night vision systems and positioning systems), Restraint Control and Sensing and Brake Systems. Its market (particularly in active safety towards autonomous driving) is characterized by a high pace of change and growth which requires an agile innovation and partnering model as well as significant upfront investments to capture future growth. It is estimated that the total available market for Safety Electronics will grow from around $20 billion in 2017 to more than $40 billion in 2025. The objective for Electronics is to capture a significant portion of that growth while continuously improving the profitability of the unit. Electronics is one of the leaders in Active Safety today with one of the broadest and most advanced product portfolios in the industry. Over the last two years Electronics has further positioned itself to be a major player in automotive electronics, including the competitiveness of the product portfolio, becoming a qualified supplier with a high number of OEM’s for active safety and entering into important partnerships with companies like Volvo Cars (Zenuity), NVIDIA and LiDAR experts Velodyne for the next generation of highly automated cars. In 2016, Electronics sales were $2.216 billion, with a target to reach $3 billion in revenue in 2020. Passive Safety consists of airbag systems, steering wheels and seatbelts. Its market is characterized by stable growth and incremental innovation which requires the highest requirements on quality and manufacturing efficiency. It is estimated that the total available market for Passive Safety will grow from around $20 billion in 2017 to around $25 billion in 2025. During the same period Passive Safety is expected to outgrow the market and light vehicle production, which is expected to grow by close to two percent annually. The objective for Passive Safety is to remain the market and innovation leader while maintaining a high level of quality and capital efficiency and further improving its margin performance. Passive Safety is the global market leader with a market share of 39% in 2016. Over the last 2.5 years Passive Safety’s share of order intake has been around 50% or more indicating significant market share expansion ahead. Standalone, Passive Safety will have increased freedom to further optimize its performance. In 2016 Passive Safety sales were $7.9 billion, with a target to reach more than $10 billion in revenues in 2020. Inquiries: Media Thomas Jönsson, Group Vice President, Corporate Communications    Tel +46 (0)8 5872 0627 Investors Ray Pekar, Vice President Investor Relations Americas    Tel +1 248 794 4537 Anders Trapp, Vice President Investor Relations    Tel +46 (0)8 5872 0671 This information is information that Autoliv, Inc. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the Group VP of Corporate Communications set out above, at 08.30 CET on December 12, 2017. About Autoliv Autoliv, Inc. is the worldwide leader in automotive safety systems, and through its subsidiaries develops and manufactures automotive safety systems for all major automotive manufacturers in the world. Together with its joint ventures, Autoliv has more than 80 facilities with 70,000 employees in 27 countries. In addition, the Company has 22 technical centers in ten countries around the world, with 19 test tracks, more than any other automotive safety supplier. Sales in 2016 amounted to about US $10.1 billion. The Company's shares are listed on the New York Stock Exchange (NYSE: ALV) and its Swedish Depository Receipts on Nasdaq Stockholm (ALIV sdb). For more information about Autoliv, please visit our company website at www.autoliv.com. Safe Harbor Statement This release contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements, including without limitation, statements related to the completion and timing of the proposed spin-off, the future performance of the Passive Safety and Electronics businesses on a stand-alone basis if the spin-off is completed; the outlook for Passive Safety and Electronics as separate businesses if the spin-off is completed; the expected strategic, operational and competitive benefits of the proposed spin-off and the effect of the separation on Autoliv and its stakeholders; management’s examination of historical operating trends and data, as well as estimates of future sales, operating margin, cash flow, effective tax rate or other future operating performance or financial results, are based upon our current expectations, various assumptions and/or data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “estimates”, “expects”, “anticipates”, “projects”, “plans”, “intends”, “believes”, “may”, “likely”, “might”, “would”, “should”, “could”, or the negative of these terms and other comparable terminology, although not all forward-looking statements contain such words. Because these forward-looking statements involve risks and uncertainties, the outcome could differ materially from those set out in the forward-looking statements for a variety of reasons, including without limitation, changes in light vehicle production; fluctuation in vehicle production schedules for which the Company is a supplier, changes in general industry and market conditions or regional growth or decline; changes in and the successful execution of our capacity alignment, restructuring and cost reduction initiatives and the market reaction thereto; loss of business from increased competition; higher raw material, fuel and energy costs; changes in consumer and customer preferences for end products; customer losses; changes in regulatory conditions; customer bankruptcies, consolidations, or restructurings; divestiture of customer brands; unfavorable fluctuations in currencies or interest rates among the various jurisdictions in which we operate; component shortages; market acceptance of our new products; costs or difficulties related to the integration of any new or acquired businesses and technologies; continued uncertainty in pricing negotiations with customers; successful integration of acquisitions and operations of joint ventures; successful implementation of strategic partnerships and collaborations; our ability to be awarded new business; product liability, warranty and recall claims and investigations and other litigation and customer reactions thereto; (including the resolution of the Toyota recall); higher expenses for our pension and other postretirement benefits, including higher funding requirements for our pension plans; work stoppages or other labor issues; possible adverse results of pending or future litigation or infringement claims; our ability to protect our intellectual property rights; negative impacts of antitrust investigations or other governmental investigations and associated litigation relating to the conduct of our business; tax assessments by governmental authorities and changes in our effective tax rate; dependence on key personnel; legislative or regulatory changes impacting or limiting our business; political conditions; dependence on and relationships with customers and suppliers; the uncertainty as to which strategic alternatives may be available with respect to the Electronics business, whether any transaction will be commenced or completed as a result of such review, and the timing and value of any such transaction; risks related to the potential separation of the Electronics business; and other risks and uncertainties identified under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Reports and Quarterly Reports on Forms 10-K and 10-Q and any amendments thereto. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any forward-looking statements in light of new information or future events, except as required by law.

Orexo discloses more information about the improved market access position for Zubsolv® US in 2018

Uppsala, Sweden – December 12, 2017 - Orexo AB today announces specific information about the improved market access position for Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) in the US effective January 1, 2018, and previously announced in the Interim Report for the third quarter of 2017. Recently the Formulary List of Covered Drugs for 2018 has been announced by all managed care programs, thus enabling Orexo to share more details about the 2018 formulary position for Zubsolv. Entering 2018, Zubsolv will have stronger market access position than ever in the US. In the commercial segment Zubsolv’s formulary access as from January 1, 2018 will be the best of any buprenorphine/naloxone products, branded or generic, with 96 percent coverage. In the fast growing public segment Zubsolv will have significant improvement in access compared to 2017 moving from 28 to 43 percent coverage (as of July 1, 2018). This progress can mainly be explained by Zubsolv´s preferred position at CVS Caremark formulary (also communicated in a press release, August 2, 2017) and by exclusive multi-year contracts with Humana Medicare Part D, Humana Commercial and Envision Rx Commercial.  The Humana Medicare Part D agreement is of high value importance to Orexo as it is the first exclusive contract within the fast growing Medicare Part D segment. Furthermore, Envision Rx,a high control PBM, will also place Zubsolv as the exclusive preferred product on their 2018 Exclusion Template Formulary List of Covered Drugs for their commercial clients. Today, these new exclusive wins combined equate to over 3 percent of the total market for buprenorphine/naloxone products. These exclusive contracts are associated with significant rebates and the impact on Orexo´s sales depends on the market share Zubsolv can obtain within each contract and the potential change in the utilization within each managed care program.   Additionally, Ohio FFS Medicaid program has announced Zubsolv will be a preferred product in parity with one other branded product, while all generics and the third branded alternative will be non-preferred on the states preferred drug list. Today, Ohio FFS Medicaid represents a small portion of the buprenorphine/naloxone prescriptions in Ohio’s Medicaid program. However, from July 1, 2018 Ohio FFS Medicaid program will direct all state Medicaid plans and provide Zubsolv access as preferred product to nearly 9 percent of the total public market which equals more than 4 percent of the total market. Today generics are market leaders in the Ohio state Medicaid plans and a significant portion of the market share gains of the generics in 2017 are from these Medicaid plans. “I am proud to share more details about the material improvements awaiting Zubsolv® at the beginning of 2018. We have learned that market access is critical to gaining market share and an important route to ensure that more patients gain affordable access to Zubsolv. With the opioid crisis in the US escalating it is vital we can offer the managed care providers a cost effective alternative, enabling them to finance treatment for more patients suffering from opioid dependence,” says Nikolaj Sørensen, CEO and President Orexo AB.   An interview with Robert DeLuca, President of Orexo US Inc, where he comments on latest developments for Zubsolv and the opioid crisis in the US is also available on our website, www.orexo.com. For further information, please contact: Orexo AB (publ.) Nikolaj Sørensen, President and CEOTel: +46 (0)18 780 88 00E-mail: ir@orexo.com Robert DeLuca, President, Orexo US, Inc.Tel: +1 973 936 6990E-mail: info-us@orexo.com About ZUBSOLV ZUBSOLV (buprenorphine and naloxone) sublingual tablet (CIII) is a prescription medication used to treat adults who are addicted to opioid drugs (either prescription or illegal) as part of a complete treatment program that also includes counseling and behavioral therapy. Treatment should be initiated under the direction of healthcare providers qualified under the Drug Addiction Treatment Act. Important safety information Do not take ZUBSOLV if you are allergic to buprenorphine or naloxone as serious negative side effects, including anaphylactic shock, have been reported. ZUBSOLV can cause serious and life-threatening breathing problems. Call your doctor right away or get emergency help if (a) you feel faint, dizzy, or confused; (b) your breathing gets much slower than is normal for you; (c) you feel sleepy and uncoordinated; (d) you have blurred vision; (e) you have slurred speech; (f) you cannot think well or clearly; or (g) you have slowed reflexes and breathing. In an emergency, have family members tell the emergency department staff that you are physically dependent on an opioid and are being treated with ZUBSOLV. ZUBSOLV contains buprenorphine, an opioid that can cause physical dependence with chronic use. Physical dependence is not the same as addiction. Your doctor can tell you more about the difference between physical dependence and addiction. Do not stop taking ZUBSOLV without talking to your doctor. You could become sick with uncomfortable withdrawal signs and symptoms because your body has become used to this medicine. Your doctor may monitor liver function before and during treatment with ZUBSOLV. ZUBSOLV is not recommended for initiation of treatment in patients with moderate hepatic impairment due to the increased risk of precipitated withdrawal. However, ZUBSOLV may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine product without naloxone. Keep ZUBSOLV in a secure place away from children. If a child accidentally takes ZUBSOLV, this is a medical emergency and can result in death. Get emergency help right away. The most common side effects of ZUBSOLV include: headache, drug withdrawal syndrome, nausea, decrease in sleep (insomnia), vomiting, pain, increased sweating, swelling of the extremities, and constipation. Tell your doctor about any side effect that bothers you or that does not go away. Opioid use may cause adrenal insufficiency, a potentially life-threatening condition. Seek immediate medical attention if you experience nausea, vomiting, anorexia, fatigue, weakness, dizziness, or low blood pressure as these are signs and symptoms that may be associated with adrenal insufficiency. Do not switch from ZUBSOLV to other medicines that contain buprenorphine without talking with your doctor. The amount of buprenorphine in a dose of ZUBSOLV is not the same as the amount of buprenorphine in other medicines that contain buprenorphine. Your doctor will prescribe a starting dose of buprenorphine that may be different than other buprenorphine-containing medicines you may have been taking. ZUBSOLV is not for occasional or “as needed” use. An overdose, and even death, can happen if you take benzodiazepines, sedatives, tranquilizers, or alcohol while using ZUBSOLV. Ask your doctor what you should do if you are taking one of these. You should not drink alcohol while taking ZUBSOLV, as this can lead to loss of consciousness or even death. Do not inject (“shoot-up”) ZUBSOLV. Injecting ZUBSOLV may cause life-threatening infections and other serious health problems. Injecting ZUBSOLV may cause serious withdrawal symptoms such as pain, cramps, vomiting, diarrhea, anxiety, sleep problems, and cravings. Before taking ZUBSOLV, tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Cases of serotonin syndrome, a rare but potentially life-threatening condition, have been reported when opioids are used along with serotonergic drugs (such as medications used to treat depression and migraines). Be sure to inform your doctor if you are taking or plan to take any serotonergic medications while taking ZUBSOLV. Before taking ZUBSOLV, tell your doctor if you are pregnant or plan to become pregnant. If you take ZUBSOLV while pregnant, your baby may have signs of withdrawal at birth and that withdrawal is treatable. Talk to your doctor if you are pregnant or plan to become pregnant. Before taking ZUBSOLV, tell your doctor if you are breastfeeding or plan to breastfeed. Nursing mothers: Caution should be exercised when buprenorphine-containing products are administered to a nursing woman. Talk to your doctor about the best way to feed your baby. If you take ZUBSOLV, monitor your baby for drowsiness and difficulty breathing. Chronic use of opioids may cause reduced fertility. It is not known whether these effects on fertility are reversible. Do not drive, operate heavy machinery, or perform any other dangerous activities until you know how ZUBSOLV affects you. Buprenorphine can cause drowsiness and slow reaction times. This may happen more often in the first few weeks of treatment when your dose is being changed, but can also happen if you drink alcohol or take other sedative drugs when you take ZUBSOLV. ZUBSOLV is a controlled substance (CIII) because it contains buprenorphine, which can be a target for people who abuse prescription medicines or street drugs. Keep your ZUBSOLV in a safe place to protect it from theft. Never give your ZUBSOLV to anyone else; it can cause death or harm them. Selling or giving away this medicine is against the law. This is not a complete list of negative side effects associated with ZUBSOLV. For a complete list please see full Prescribing Information . To report negative side effects associated with taking ZUBSOLV, please call 1-888-982-7658. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit ww.fda.gov/medwatch or call 1-800-FDA-1088. For more information about ZUBSOLV (buprenorphine and naloxone) Sublingual Tablet (CIII), please see the respective full Prescribing Information  and Medication Guide  at www.zubsolv.com . About Orexo Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden. For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. About Orexo US, Inc. Orexo US, Inc. is an emerging specialty pharmaceutical company marketing improved treatments for opioid dependence using proprietary drug delivery technology. To receive more information please contact Orexo at 1-855-ZUBSOLV. www.orexo-us.com  The information was submitted for publication at 8:30 am CET, December 12, 2017

Press release; Senzime receives CE mark approval for the TetraGraph

Lena Söderström, CEO of Senzime states, "The CE mark is a major milestone for Senzime, we will immediately commence the market roll-out of the TetraGraph system initially in Europe followed by the US and rest of the world. The TetraGraph will allow physicians to monitor the effects of neuromuscular blocking drugs perioperatively and ensure that patients can breathe spontaneously which will prevent complications and hence lower healthcare costs”.The TetraGraph neuromuscular monitor is a unique system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph stimulates a peripheral nerve and measures, analyzes and displays the muscle function in surgical patients who receive NMBAs as part of their general anesthetic. “We look forward to use the TetraGraph routinely, since the device is very easy to use, saves us time with the quick set-up and provides invaluable clinical information,” says Prof. Bela Fulesdi, Chairman of the Department of Anesthesiology and Intensive Care, Debrecen University Hospital, Debrecen, Hungary.  Every year, over 70 million surgical patients undergo general anesthesia and receive neuromuscular blocking drugs. Without objective monitoring (the ability to measure and analyze the evoked muscle responses) over 30 percent of these patients experience postoperative complications. The TetraGraph system will enable physicians to assure sufficient return of neuromuscular function of patients, and avoid these postoperative complications.Senzime has previously entered distribution agreements for TetraGraph in the UK, Ireland, Switzerland, Australia and New Zealand, and licensing agreements in Japan. Discussions are ongoing with distributors for additional markets and additional agreements are expected during the following quarter. For further information, please contact: Lena Söderström, CEO of Senzime AB Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com TO THE EDITORS About Senzime Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com  This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on December 12 2017.

Autoliv declares dividend and sets date for shareholder AGM

The dividend will be payable on March 8, 2018, to holders of record at the close of business on February 22, 2018. The Board of Directors has set Tuesday May 8, 2018 as the date for its annual meeting of shareholders to be held in Chicago, IL, USA. Only shareholders of record at the close of business on March 12, 2018 will be entitled to be present and vote at the meeting. Notice of the annual meeting will be mailed to holders of record in late March. Inquiries: Thomas Jönsson, Group Vice President Communications    Tel +46 (0)8 58 72 06 27 This information is information that Autoliv, Inc. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, at 09.00 CET on December 12, 2017. About Autoliv Autoliv, Inc. is the worldwide leader in automotive safety systems, and through its subsidiaries develops and manufactures automotive safety systems for all major automotive manufacturers in the world. Together with its joint ventures, Autoliv has more than 80 facilities with 70,000 employees in 27 countries. In addition, the Company has 22 technical centers in ten countries around the world, with 19 test tracks, more than any other automotive safety supplier. Sales in 2016 amounted to about US $10.1 billion. The Company's shares are listed on the New York Stock Exchange (NYSE: ALV) and its Swedish Depository Receipts on Nasdaq Stockholm (ALIV sdb). For more information about Autoliv, please visit our company website at www.autoliv.com. Safe Harbor Statement” This report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any such statements in light of new information or future events, except as required by law.

Arjo AB (publ) listed on Nasdaq Stockholm

The medical device company Arjo AB (publ) (“Arjo”), formerly part of the Getinge Group, has today been listed on Nasdaq Stockholm and the company’s shares of series B have been admitted to trading. At an Extraordinary General Meeting of Getinge AB on December 4, 2017, the shareholders resolved to distribute all of the shares in Arjo to the shareholders of Getinge. The Getinge Group is thereby divided into two listed companies, Getinge and Arjo, which is expected to increase the potential to successfully develop each business. All of the shares of the wholly owned subsidiary Arjo, including the underlying Group, will be distributed to Getinge shareholders according to the Lex ASEA rules* and shares of series B in Arjo have now been admitted to trading on Nasdaq Stockholm. Arjo is a global supplier of medical devices and solutions that improve quality of life for people with reduced mobility and age-related health challenges. Arjo’s work is based on genuine care for peoples’ health and well-being, and contributes to a sustainable healthcare system — always with people in mind. “As a standalone, independent company, Arjo can achieve what is required to develop the business in the right direction. With a clearer focus, we will have better opportunities to realize our strategy and efficiently develop products and solutions, and thus create positive customer and shareholder value” says Joacim Lindoff, President and CEO of Arjo.  Arjo was founded in 1957 in Eslöv by entrepreneur Arne Johansson. Arjo has since evolved into a global player in the market, with extensive knowledge about how to care for and improve quality of life for people with reduced mobility and age-related health challenges. Today, Arjo operates in a market featuring stable and high demand. There is much to indicate that global demand for healthcare and elderly care will continue to rise in the foreseeable future. Growth is largely being driven by demographic factors such as an aging population and higher incidence of chronic diseases. The economic performance of emerging markets is also enabling more countries to develop advanced healthcare. “I am very proud and honored. The organisation has done a fantastic job – this is a big day for us at Arjo. I look forward to an exciting and successful future with Arjo” concludes Joacim Lindoff. * Lex ASEA means, in brief, that a parent company can, under certain circumstances, distribute the company’s shares in a subsidiary to its shareholders without any immediate Swedish taxation arising on the distribution for the shareholders.  For further information, please contact:  Kornelia RasmussenExecutive Vice PresidentMarketing Communication and Public RelationsTel: +46 (0)10 335 48 10E-mail: kornelia.rasmussen@arjo.com  About Arjo  At Arjo, we are committed to improving the everyday lives of people affected by reduced mobility and age-related health challenges. With products and solutions that ensure ergonomic patient handling, personal hygiene, disinfection, diagnostics, and the effective prevention of pressure ulcers and venous thromboembolism, we help professionals across care environments to continually raise the standard of safe and dignified care. Arjo has over 5,900 employees worldwide and customers in over 60 countries. In 2016 the Arjo sales amounted to about SEK 8 billion. Arjo is listed on Nasdaq Stockholm and its head office is located in Malmö, Sweden. Everything we do, we do with people in mind. www.arjo.com  

Episurf Medical reaches milestone of 300 implants

Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of its 300th surgery with the Episealer® implant in the coming weeks. “Strong clinical results, a growing user group among European surgeons, our 300th implant in production, a significant increase in the interest for the Episealer® technology within the orthopaedic industry, and most importantly, a continuous flow of successful patient outcomes. All of this sums it up, Episurf Medical is continuing to establish the Episealer® technology as a treatment alternative for early knee cartilage and bone damages“ says Pål Ryfors, CEO Episurf Medical. For more  information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 09.30 CET on 12 December 2017.

Finnair Brings Apple Pay to Customers

Finnair today brings its customers Apple Pay, which is transforming mobile payments with an easy, secure and private way to pay that’s fast and convenient. Finnair customers can now use Apple Pay for ticket and ancillary purchases on Finnair’s mobile website and using the Finnair mobile application. Apple Pay is available for Finnair customers using iOS mobile devices globally in those markets where Apple has implemented the payment method.   Security and privacy is at the core of Apple Pay. When you use a credit or debit card with Apple Pay, the actual card numbers are not stored on the device, nor on Apple servers. Instead, a unique Device Account Number is assigned, encrypted and securely stored in the Secure Element on your device. Each transaction is authorized with a one-time unique dynamic security code. “Apple Pay is widely used in several countries, and for us it is a natural addition to the payment methods available for the growing number of customers using our services with Apple mobile devices. Mobile payments are growing in popularity, and it fits well into our digital services,” says Katri Harra-Salonen, Finnair Chief Digital Officer.Apple Pay is easy to set up and users will continue to receive all of the rewards and benefits offered by credit and debit cards. In stores, Apple Pay works with iPhone SE, iPhone 6 and later, and Apple Watch.   Online shopping in apps and on websites accepting Apple Pay is simple with Touch ID, or just double-click the side button and glance at your iPhone X to authenticate with Face ID. There’s no need to manually fill out lengthy account forms or repeatedly type in shipping and billing information with Apple Pay. When paying for goods and services on the go in apps or Safari, Apple Pay works with iPhone 6 and later, iPhone SE, iPad Pro, iPad (5th Generation), iPad Air 2, and iPad mini 3 and later. You can also use Apple Pay in Safari on any Mac introduced in or after 2012 running macOS Sierra and confirm the payment with iPhone 6 or later or Apple Watch, or with Touch ID on the new MacBook Pro. For more information on Apple Pay, visit: http://www.apple.com/apple-pay/  

Update on financial calendar and lender dialogue in Viking Supply Ships AB

As previously communicated, the company's subsidiary Viking Supply Ships A/S is in discussions with its senior lenders regarding the long term financing of the company. Viking Supply Ships A/S has now obtained support for a restructuring proposal from all senior lenders. Subject to final approval from the senior lenders’ credit committees, the Group therefore expects the financial restructuring to be finalized within short. The main principles of the restructuring proposal includes that Viking Supply Ships will receive MUSD 15 in new equity through the already announced rights issue. In addition there will be significant reductions in interest payments and amortizations during a period until Q1 2020. Financial covenants on the loan facilities are also amended to provide Viking Supply Ships A/S with ample room to operate under the present challenging market conditions. As communicated in the press release as of 29 November, the publication of the Q3 2017 interim report was postponed due to the ongoing dialogue with the senior lenders. With the principle agreement with the senior lenders in place, The Group expects the report to be published 18 December 08:30. In conjunction with the publication of the Q3 2017 report, an earnings call will take place on 18 December at 10:00 am (CET). Following the postponement of the reporting date for Q3 2017, the board of directors has decided to make use of the authorization from the general meeting and amend the previously communicated proposed timeline regarding the new issues of shares and extend the subscription period for the rights issue as set out below. The reason for such extension of the subscription period is to allow for the shareholders to take into consideration the financial report for Q3 2017. Updated indicative timeline for the rights issue: 18 December    Publication of the financial report for Q3 2017 21 December    Estimated date for publication of prospectus supplement 22 December    Trading in subscription rights ends 28 December    Subscription period ends   2 January        Estimated date for announcement of preliminary results of subscriptions For further information regarding the financial calendar, please see: http://www.vikingsupply.com/investorrelations. For further information please contact:   Ulrik Hegelund, CFO, ph. +45 41 77 83 97, e-mail ulrik.hegelund@vikingsupply.com  Morten G. Aggvin, IR & Treasury Director, ph. +47 41 04 71 25, e-mail ir@vikingsupply.com  Viking Supply Ships AB is the parent company of a Swedish shipping group with its main office in Gothenburg, Sweden. The Group conducts its business in four segments: Anchor Handling Tug Supply ships (AHTS), Platform Supply Vessels (PSV), Services and Ship Management. The business is focused within offshore and ice-breaking primarily in Arctic and subarctic areas. The Group has approximately 400 employees and its revenue for 2016 amounted to MSEK 760. The Company’s series B share is listed at Nasdaq Stockholm, Small Cap segment. www.vikingsupply.com. This information is information that Viking Supply Ships AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11:10 CET on 12 December 2017.

Gothenburg Professor awarded 50 million Swedish kronor for research into innovation and entrepreneurship

The Swedish Research Council announced their Distinguished Professors last week. Professor Maureen McKelvey has been chosen as one of them. McKelvey is Professor of Industrial Management at the University of Gothenburg and also recently inducted into the Royal Swedish Academy of Engineering Sciences. ”This is a tremendous honor for me, and also for my colleagues and the University of Gothenburg as a whole. We have the opportunity to make a lasting investment in an area that is extremely important for societal development, both here locally in Gothenburg and nationally in Sweden as well as globally.” McKelvey’s research program can now become a reality thanks to the Swedish Research Council. Her program is called Entrepreneurial ecosystems: Transforming society through knowledge, innovation and entrepreneurship. The aim is to update the theoretical and empirical understanding of how knowledge-intensive entrepreneurial ecosystems can be established and maintained in order to meet future societal challenges. Society is always changing, and is under numerous pressures of digitalization, globalization and regionalization. To succeed, we must be daring in our research approach. “My vision for the coming decade is to explain how and why knowledge intensive entrepreneurs influence, and are influenced, by novel ideal types of entrepreneurial ecosystems. I will do so by extending evolutionary theory, where processes for creating and transforming knowledge are central, as well as a bold approach to integrate qualitative and qualitative methods, in order to deliver on results of great significance to society.” The Swedish Research Council’s Distinguished Professors Program will create the conditions for the most distinguished researchers to engage in long-term, innovative research with great potential to achieve scientific breakthroughs. The grant will also promote the establishment and development of a research environment of highest quality. The Distinguished Professorships have only been awarded three times, and of a total of 539 applications, only 29 have been granted. The vast majority of grants go to medicine, engineering and natural science. Only three have ever been awarded within the humanities and social sciences, include the one to Professor McKelvey. “It is a fantastic honor to be awarded this grant! Very few grants of this size are awarded to the social sciences, and it is even more of a rarity that they go to a relatively new field such as entrepreneurship and innovation. This is a powerful signal that entrepreneurship and innovation’s place in research is quickly advancing, and will also affect society in the future.” Professor McKelvey would also like to thank her research partners and financiers through the years – Carl Bennet, Chalmers, European Union, GU Ventures, IMIT, Riksbankens Jubileumsfond, SKF, Sten A Olsson Foundation for research and culture, VINNOVA, Volvo AB and the Richard C Malmsten Memorial Foundation. About Professor Maureen McKelveyMaureen McKelvey is Professor of Industrial Management at the School of Business, Economics and Law at the University of Gothenburg. She was previously Professor of Economics of Innovation at Chalmers (2002-2007). In 1996, McKelvey won the prestigious Schumpeter Prize, awarded by the International Joseph A. Schumpeter Society. She has published a dozen books and a very large number of scientific articles. McKelvey has been member of the boards in many of the prestigious scientific associations and international research centers in her field. McKelvey has been active in a large number of public policy reports, meetings, panels and evaluations, especially in Sweden and the European Union but also in Asia. McKelvey has a BA in Economics and Political Science from Rice University, USA; a MSc in Science and Technology Policy från Lund University, Sweden; and a PhD in the interdisciplinary area of Technology and Social Change from Linköping University, Sweden. Member of IVA since December 2017. Professor McKelvey works at the Department of Economy and Society, (www.handels.gu.se/iie). For more information, please contact:Maureen McKelvey, maureen.mckelvey@handels.gu.se

SensoDetect - Version 3.0. A new compact, portable version of SensoDetect BERA is here!

In the development work, we have, based on the proven basic design of the existing system, modernized and streamlined the system radically while eliminating bottlenecks in the signal paths. New firmware has been developed for the new version. V3.0 is designed for rational industrial production with all components on a single circuit board. V3.0 is now undergoing an internal validation. The basic structure is essentially the same as in previous versions. Existing documentation will be able to be used in the CE process, which significantly reduces the time for the process."I am very pleased that the development work has been conducted at a high pace. SensoDetect can shortly offer users a truly modern, portable and compact version of the unique SensoDetect BERA system in a brand new form; V3.0. A portable system that is also suitable for use in the field. The product has all components on a circuit board, can be machine assembled in its entirety and is therefore very cost effective. The new software makes it possible to use SensoDetect Bera V3.0 with a portable PC or touch pad, which makes the product compact and flexible. The new product has features built-in to ensure that all electrodes are properly applied to the patient and that the measurements are of optimal quality. Our validations so far are very promising, the product is stable and the results show highly reproducible. "Says Johan Olson, CEO, SensoDetect AB (publ.).

Elekta and Stockholm County Council agree on constructive way forward

Elekta will continue to fully equip the new radiation therapy department of Stockholm South General Hospital (SöS) and to provide brachytherapy solutions to New Karolinska Solna (NKS). Stockholm County Council will have the possibility to seek a separate solution for the remaining external beam equipment at NKS. Richard Hausmann, Elekta President and CEO, commented: “The Letter of Intent provides both parties with a constructive way to move forward and collaborate for Stockholm County Council to expand cancer care services. As a Stockholm-based company we look forward to continue providing advanced, world-class cancer care to the patients of Stockholm.” The Letter of Intent is expected to be turned into a binding contract latest January 31, 2018. The value of the remaining part of the contract is expected to be approximately SEK 160 million; the initial order value was approximately SEK 350 million over the 13-year lifetime of the agreement. # # # For further information, please contact:Gert van Santen, Group Vice President Corporate Communications, Elekta ABTel: +31 653 561 242, e-mail: gert.vansanten@elekta.comTime zone: CET: Central European TimeTobias Bülow, Director Financial Communications, Elekta ABTel: +46 722 215 017, e-mail: tobias.bulow@elekta.comTime zone: CET: Central European Time This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 13:00 CET on December 12, 2017. (REGMAR)About ElektaElekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com

Citycon decided on a quarterly distribution

The Board of Directors of Citycon Oyj has today decided, on the basis of the authorisation by the Annual General Meeting 2017, that an equity repayment of EUR 0.0325 per share be distributed from the invested unrestricted equity fund of the company. The equity repayment will be paid to a shareholder registered in the company’s shareholders’ register maintained by Euroclear Finland Ltd on the record date for the dividend and equity repayment 14 December 2017. The equity repayment will be paid on 29 December 2017.Citycon’s Annual General Meeting held on 22 March 2017, resolved to authorise the Board of Directors to decide in its discretion on the distribution of dividend and equity repayment. Based on the authorisation the total amount of the dividend to be distributed shall not exceed EUR 0.01 per share and the maximum amount of equity repayment distributed from the invested unrestricted equity fund shall not exceed EUR 0.12 per share. The authorisation is valid until the opening of the Annual General Meeting 2018.Following the asset distribution on 29 December 2017, Citycon Oyj has distributed a total dividend and equity repayment of EUR 0.13 per share during the year 2017 and the Board of Directors has fully exercised the asset distribution authorisation granted by the Annual General Meeting.CITYCON OYJFor further information, please contact:Marcel Kokkeel, CEOTel. +358 40 154 6760marcel.kokkeel@citycon.comEero Sihvonen, Executive Vice President and CFOTel. +358 50 557 9137eero.sihvonen@citycon.comCitycon is a leading owner, manager and developer of urban, grocery-anchored shopping centres in the Nordic and Baltic region, managing assets that total almost EUR 5 billion and with market capitalisation of close to EUR 2 billion. Citycon is No. 1 shopping centre owner in Finland and among the market leaders in Norway, Sweden and Estonia. Citycon has also established a foothold in Denmark.Citycon has investment-grade credit ratings from Moody's (Baa1) and Standard & Poor's (BBB). Citycon Oyj’s share is listed in Nasdaq Helsinki.www.citycon.com

Stora Enso refinances its revolving credit facility

Stora Enso has today signed a new EUR 600 million revolving credit facility agreement with a syndicate of 13 banks to refinance its existing EUR 700 million facility. The new facility matures in January 2023 and will be used as a backup for general corporate purposes. The loan has no financial covenants. BNP Paribas, Citi and SEB acted as Coordinators, Bookrunners and Mandated Lead Arrangers for the facility, while Barclays Bank PLC, Crédit Agricole Corporate and Investment Bank, Deutsche Bank, DBS Bank Ltd, London Branch, DNB Bank ASA, Goldman Sachs, J.P. Morgan Securities plc, National Westminster Bank PLC, Nordea Bank AB (publ) and OP joined in syndication as Mandated Lead Arrangers. “We are pleased with the continued support and commitment of our relationship banks. Improving the terms of the facility and extending maturity even longer adds flexibility during Stora Enso’s transformation,” says Group Treasurer Martin Ros. For further information, please contact:Martin Ros, SVP, Group Treasurer, tel. +46 1046 71078 Investor enquiries:Ulla Paajanen-Sainio, SVP, Investor Relations, tel. +358 40 763 8767 Stora Enso is a leading provider of renewable solutions in packaging, biomaterials, wooden constructions and paper on global markets. Our aim is to replace fossil-based materials by innovating and developing new products and services based on wood and other renewable materials. We employ some 25 000 people in more than 35 countries, and our sales in 2016 were EUR 9.8 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com   STORA ENSO OYJ 

Caverion updates its guidance for 2017

Caverion updates its guidance for 2017 Caverion Corporation updates its guidance for 2017. Caverion now expects that its Group EBITDA excluding restructuring costs will grow clearly (15-30%) or significantly (30-100%) compared to last year in 2017 (2016: EUR 15.6 million). Previous profitability guidance was that the Group’s EBITDA excluding restructuring costs will more than double in 2017 (2016: EUR 15.6 million). The previous revenue guidance remains unchanged. Caverion estimates that the Group’s revenue will remain at the previous year's level in 2017 (2016: EUR 2,364 million).  In line with its strategy, Caverion has continued its selective approach towards the Projects business in the fourth quarter of 2017. Caverion has also continued implementing its corrective actions to improve its project business performance, but the Group result is still burdened by write-downs related to certain older projects. At the same time, the Group’s cash flow is improving and the Services business is continuing to develop positively. “Caverion’s financial performance in 2017 is negatively impacted mainly by our project business performance. At the same time we have started to build a new stronger Caverion for the future. Our “Fit for Growth” strategy is progressing forward according to plan,” says Ari Lehtoranta, President and CEO of Caverion Corporation.  Caverion’s new guidance for 2017: Caverion estimates that the Group’s revenue will remain at the previous year's level in 2017 (2016: EUR 2,364 million). Caverion estimates that the Group’s EBITDA excluding restructuring costs will grow clearly or significantly compared to last year in 2017 (2016: EUR 15.6 million). Previous guidance for 2017: Caverion estimates that the Group’s revenue will remain at the previous year's level in 2017 (2016: EUR 2,364 million). Caverion estimates that the Group’s EBITDA excluding restructuring costs will more than double in 2017 (2016: EUR 15.6 million). In its guidance Caverion applies the following guidance terminology, with a +/- 2pp (percentage point) threshold to the said limits. +------------------------+-----------+-----------+|Positive change   |Lower limit|Upper limit|+------------------------+-----------+-----------+|% | %|+------------------------+-----------+-----------+|At last year’s level  | -5%| 5%|+------------------------+-----------+-----------+|Grows  | 5%| 15%|+------------------------+-----------+-----------+|Grows clearly  | 15%| 30%|+------------------------+-----------+-----------+|Grows significantly  | 30%| 100%|+------------------------+-----------+-----------+|Doubles  | 100%| |+------------------------+-----------+-----------+| | | |+------------------------+-----------+-----------+|Negative change |Lower limit|Upper limit|+------------------------+-----------+-----------+|% | %|+------------------------+-----------+-----------+|Decreases  | -15%| -5%|+------------------------+-----------+-----------+|Decreases clearly  | -30%| -15%|+------------------------+-----------+-----------+|Decreases significantly | | -30%|+------------------------+-----------+-----------+ Publication of the Financial Statement Release for 2017: Caverion will publish its Financial Statement Release for 2017 on Wednesday, February 7, 2018 at approximately 8.00 a.m. Finnish time (EET). CAVERION CORPORATION Distribution: Nasdaq Helsinki, principal media, www.caverion.com 

NCC increases provisions in construction and civil engineering projects and reduces overhead costs

The Acting Business Area Manager of NCC Infrastructure, Göran Landgren has endeavored to turn around the business area’s weak earnings trend since the start of September. Following a review of both completed and ongoing projects, a need to establish provisions has now been identified ahead of the closing of the annual accounts. A revaluation of the ongoing project portfolio of SEK 260 million will be charged to the business area’s earnings in the fourth quarter, of which SEK 150 pertains to road and land projects and SEK 110 million to major civil engineering projects. NCC Infrastructure is expected to report an operating loss of approximately SEK 100 million for the fourth quarter. Earnings for the NCC Building business area will also be charged with SEK 55 million in the fourth quarter for provisions in construction projects, primarily attributable to the Danish operations. Operating profit is expected to amount to approximately SEK 200 million for the fourth quarter. The higher provisions mean that the project portfolios in NCC’s construction and civil engineering operations will have a lower and more balanced risk. These provisions do not impact fourth-quarter cash flow. As stated in the most recent interim report, NCC will apply the new accounting standard IFRS 15 Revenue from Contracts with Customers from January 1, 2018. An analysis of the effects of the standard is in progress and will be presented in the year-end report. NCC Industry is expected to report operating profit in line with the fourth quarter of 2016. As previously announced, NCC Property Development has no property projects to recognize in profit in the fourth quarter, thus yielding an operating loss of about SEK -50 million. NCC’s overhead costs are too high at the current rate of growth and these costs will thus be reduced, resulting in annual savings of approximately SEK 200 million. The purpose of the cost reduction is to ensure an overhead cost level of a maximum of 5 percent of sales. Restructuring costs of approximately SEK 75 million will be charged against earnings for the fourth quarter. These restructuring costs also include severance pay for the former CEO. In 2015, NCC launched a new strategy with the target of annual sales growth of 5 percent and improving the operating margin from 3 to at least 4 percent. “For our strategy to be successful, our construction and civil engineering operations must perform well. These operations have delivered on targets for orders received but earnings have been weak. Focus going forward will be concentrated to improving profitability and maintaining the growth ambitions of the strategy plan is not a priority. Alongside improving profitability, work environment and safety are key priorities,” says Håkan Broman, Acting President and CEO of NCC AB. A teleconference will be held today, Wednesday, December 13 at 8:30 a.m. NCC’s Acting President and CEO, Håkan Broman, and CFO, Mattias Lundgren, will respond to questions. To participate in this teleconference, call +46 8 519 993 55 (SE), +44 203 194 05 50 (UK) or+1 855 269 26 05 (US). All other information related to the fourth quarter of 2017 will be presented in NCC’s 2017 year-end report on January 25, 2018.

IRRAS announces voluntary recall on its IRRAflow™ device due to an isolated incident of a battery manufacturing failure

IRRAS AB (IRRAS), a commercial-stage medical technology company focused on designing, developing and commercializing innovative solutions for various brain pathologies, announces that it has notified customers of a voluntary recall and a temporary stop of selling of IRRAflow™, the company’s closed-circuit medical device for the treatment of intracranial bleedings. The reason for the voluntary recall is that the battery, supplied by a well validated external manufacturer, overheated on an IRRAflow™ control unit while charging in standby mode during a routine office demonstration. No patients were present and no procedures were scheduled, as this was only an office demonstration. IRRAS is taking this action as a precaution. IRRAS is now working with the battery supplier to understand the specific cause for the failure of the battery. As part of our quality systems all batteries undergo charge and discharge testing as well as a 24-hour use period to screen for any potential manufacturing defects. Therefore, IRRAS believes this is an isolated incident of a manufacturing failure. Relevant regulatory bodies will be notified of the voluntary recall. As a reminder of the impact IRRAflow™ has on neurosurgery critical care of intracranial bleedings, to date, IRRAflow™ has been used in 94 clinical procedures in four different EU countries. There have been no occlusions or blockages in the catheters and no infections reported. Of the 94 real-world clinical cases, the total treatment time in the hospital for each patient was significantly reduced from the current standard of care treatment. IRRAS does not anticipate any long-term impact in the adoption and clinical use of its IRRAflow™ device due to this isolated incident, especially given the successful clinical usage thus far, and expects sales to resume as soon as the new batteries are available. The voluntary recall will affect the 2017 sales of IRRAflow™ on two fronts, both as the sales have now temporary stopped and IRRAS has offered to repurchase the previously sold products. The company has already initiated a process to replace the specific lot of batteries in the control units. IRRAS estimates that the replacement and validation of the new lot can be ready within 1 to 3 months, therefore delaying the sales plan accordingly. The 2020 objective of sales exceeding 250 MSEK remains intact. About IRRASIRRAS is a commercial-stage medical technology company focused on designing, developing and commercializing innovative solutions for various brain pathologies, with a goal of dramatically improving patient outcomes, reducing patient-time in the intensive care unit and medical ward, and providing significant health economic benefits to hospitals and healthcare providers. The Company’s initial product focus is on intracranial fluid management solutions that utilize its proprietary platform technology, IRRAflow™, which is a CE-marked, fully integrated, closed-circuit medical device system that enables intelligent intracranial fluid management as well as accurate, real-time monitoring of intracranial pressure. With its unique product portfolio, protected by key intellectual property patents and patent applications, IRRAS is well-positioned to improve patient outcomes and establish a leadership position in the medical device market. IRRAS maintains its headquarters in Sweden with corporate offices in Germany and La Jolla, CA, USA. For more information, please visit www.irras.com. Investor and Media Contact:Fredrik AlpstenCFO and Deputy CEO+46 706 67 31 06fredrik@irras.com  This information is information that IRRAS is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on 13 December 2017 at 07.25 a.m. (CET).

BONESUPPORT™ ACHIEVES AIM OF RECRUITING 136 PATIENTS INTO THE CERTiFy STUDY COMPARING CERAMENT®|BONE VOID FILLER WITH AUTOGRAFT

Lund, Sweden, 08.00 CET, 13 December 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces that it has achieved its aim of recruiting 136 patients into the CERTiFy (CERAMENT® Treatment of Fracture defects) study.   CERTiFY is a prospective, randomized, controlled clinical study designed to compare the differences in pain, quality of life, and cost of care in the treatment of tibia plateau fracture-associated bone defects using either CERAMENT®|BONE VOID FILLER (CERAMENT BVF) or autologous bone grafting (autograft). Autograft is the current gold standard for bone graft procedure for the management of tibia plateau fractures. The primary outcome of the study is based on data from the SF-12 Physical Component Summary, which assesses the patient’s physical functioning, at week 26. The co-primary endpoint is the pain level 26 weeks after surgery measured by a visual analog scale. The SF-12 Mental Component Summary after 26 weeks and the costs of care will serve as key secondary endpoints. Initial top-line data from the study is expected towards the end of 2018. A publication providing more complete data from the CERTiFy study is expected in Q1 2019.  The CERTiFy study recruited patients from 20 top orthopedic trauma centers in Germany. Professor Pol. M. Rommens, Head of The Department of Orthopaedics and Traumatology at The University Medical Centre Mainz is the study’s Principle Investigator. Professor P.M. Rommens said: “Bone graft substitutes, such as CERAMENT BVF, are widely used for reconstruction of post-traumatic bone defects. However, their clinical significance in comparison to autograft, the gold-standard in reconstruction of larger bone defects, is still the subject to debate. With CERTiFy we aim to demonstrate that CERAMENT BVF is non-inferior to autograft across a range of clinical parameters. If achieved, this would be a major advance in the treatment of post-traumatic bone defects given the fact that not two but only one operative procedures are needed for filling up the defect.  I am looking forward to reporting the initial results from the study.” BONESUPPORT CEO Richard Davies said: "We are pleased to have achieved this important milestone in the CERTiFy study that demonstrates BONESUPPORT’s ability to run significant complex multi-centre studies and generate Level I data that has the potential to change the practice of medicine. We are confident that positive data from CERTiFy would lead to much greater uptake of all CERAMENT products across multiple trauma indications due to their ease of use and lower procedure costs.”

Idogen has been granted a patent in the USA for its immune therapy technology

The United States Patent & Trademark Office (USPTO) issued in March 2017 a “Notice of Allowance” and has now formally granted a patent, US 9,839,674, for Idogen’s Patent Application No. 14/553,098. The patent belongs to Idogen’s second patent family and covers the use of the company´s immune technology for treatment of autoimmune diseases and tolerance of transplanted organs. The patent term extends to December 20, 2031. A related patent application is pending in Canada. The granted patent complements the Japanese and European granted patents in this family and an earlier European patent in Idogen’s first patent family, granted in December 2013.   “The patent now granted provides strong intellectual property protection in the world's largest pharmaceutical market, thereby significantly increasing the commercial potential of our innovative tolerogenic immunotherapies”, Idogen´s CEO Lars Hedbys comments. For additional information, please contact: Lars Hedbys, CEO Idogen AB Tel: +46 (0)46-275 63 30 E-mail: lars.hedbys@idogen.com This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 12th of December 2017. Idogen develops tolerogenic immune therapies which re-program the immune system. The term "tolerogenic" refers to that the immune system will tolerate the selected molecule after treatment. It represents a new treatment method for severe diseases with a large medical need currently lacking cure – such as autoimmune diseases, organ rejection after transplantation and patients without treatment after developing antibodies against standard treatment.The treatment method comprises cells from the patient's blood being reprogrammed to dendritic cells with the capacity to specifically counteract the adverse immune reaction, without affecting the other immune function. The first indication for the therapy will be patients with the bleeding disorder hemophilia A who have developed an immunological reaction against their necessary factor VIII replacement. The company's next therapeutic area will be a tolerogenic vaccine to counteract organ rejection in transplantation, primarily kidney transplantation. Idogen’s tolerogenic immune therapy is expected to reduce the need for immunosuppressive therapy and increase transplant survival, and thereby reduce the risk of cancer and serious infections. Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University. For more information, visit www.idogen.com

Axactor Group secures significant consumer portfolio in Italy

Oslo, 13th December 2017 - Axactor Italy, an Axactor group company, has acquired a significant portfolio of unsecured consumer claims from a large financial institution in Italy. The portfolio has an outstanding balance of approximately EUR 90m across 20.000 cases and represents Axactor's largest acquisition in Italy since acquiring CS Union in 2016. This acquisition will generate an increase in the volumes of cases under management and will benefit both the amicable and legal workstreams, which are both very important in Italy. Massimiliano Ciferri, country manager Italy, commented "This acquisition marks a significant investment for Axactor Group in Italy and one on which we believe we can build on to generate further purchases. The new management team in Axactor are extremely excited to have successfully acquired such a high quality portfolio. " The investments will be financed by Axactor Italy's existing credit facilities. For additional information, please contact: Endre Rangnes, CEO Axactor Mobile phone: +47 4822 1111 Email: endre.rangnes@axactor.com or Geir Johansen, CFO & Investor Relations, Axactor Mobile phone: +47 4771 0451 Email: geir.johansen@axactor.com www.axactor.com About Axactor Axactor Group specializes in both Debt Collection and Debt Purchasing across several countries, with operations in Italy, Germany, Norway, Sweden and Spain. The company has a Nordic base and an ambitious Pan-European growth strategy, which targets the market for non-performing loans (NPL) in Europe. This market is estimated to be about 1,500 billion euros across Europe providing significant opportunities for Axactor's future expansion. Axactor has approximately 900 employees.

NeuroVive’s KL1333 program granted orphan drug designation by the European Commission

The decision by the Commission confirms the opinion previously issued by the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP), which was communicated by NeuroVive on 8 November 2017. The orphan drug designation for KL1333, together with NeuroVive’s status as a micro, small and medium-sized enterprise (SME), offers NeuroVive access to free scientific advice (protocol assistance) from the EMA, as well as fee reductions and further administrative assistance from EMA’s SME office. If approved for orphan drug status when authorized for marketing, KL1333 would benefit from ten years of market exclusivity within the European Union. KL1333 is being developed jointly by NeuroVive and the Korean pharmaceutical company Yungjin Pharm. KL1333 has shown promising results in preclinical models and a clinical phase I study is currently being conducted in Korea. NeuroVive plans to initiate the next clinical phase I study in 2018. For more information, please contact: Daniel Schale, Director of Communications +46 (0)46-275 62 21, ir@neurovive.com NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) info@neurovive.com, www.neurovive.com This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CET on 13 December 2017. About KL1333  KL1333 is a potent modulator of the cellular levels of NAD+, a central coenzyme in the cell’s energy metabolism. KL1333 has in preclinical models been demonstrated to increase mitochondrial energy output, reduce lactate accumulation, diminish the formation of free radicals, and to have long-term beneficial effects on energy metabolism such as the formation of new mitochondria. It is in clinical development stage intended to document the use for chronic oral treatment in primary genetic mitochondrial disorders such as MELAS, KSS, CPEO, PEO, Pearson and MERRF. Its mode of action is complementary to that of NVP015, which is intended to alleviate acute episodes of energy crises in genetic mitochondrial disorders with dysfunction in respiratory complex I and to NVP025, intended to protect the mitochondria in skeletal muscle from dysfunctional calcium handling and consequential muscle wasting. About Yungjin Pharm Yungjin Pharm Co. Ltd., established in 1952, has been playing a major role as a forerunner in the Korean pharmaceutical industry for half a century. With the inspiring mission statement, "To relieve the suffering of mankind from diseases with our innovative, effective and safe pharmaceutical products", they have shown a successful contribution not only within Korea, but also through global expansion. As a result, they have received a total of 25 awards including the President Award for Superior Product Development, the Prime Minister Award, Industry Award and many more. These accomplishments demonstrate their sustainability and commitment to the development of innovative products and business excellence in both overseas and domestic segments. The company is listed on the South Korean stock market, KOSPI (KRX 003520). About NeuroVive  NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

Arkessa, Brighter, Ericsson and Gemalto partner to provide global connectivity solutions for Actiste.

Brighter AB have selected the Arkessa eUICC solutions to support the global market launch of Actiste, a mobile health solution that simplifies insulin-treated diabetes by gathering and sharing personal health data between patient and healthcare professionals through a connected pocket-sized device. Actiste will be marketed and sold as a service to both consumers and the healthcare sector across the globe. The flexibility offered by eUICC is critical to simplifying the go-to-market process and the customer experience by ensuring out-of-the-box connectivity, but also localising that connectivity. The ability to secure and localise connectivity and personal data is a fundamental requirement for governments and consumers particularly in healthcare. For example, in Europe, the May 2018 deadline for EU General Data Protection Regulation (GDPR) compliance is edging ever closer. Under those regulations, organisations will need to document and report on where their data is, how it is collected, how it is stored, and who can access it, in transit and at rest. This is not unique to Europe of course. By enabling organisations to control which mobile networks are used for data communications, the eUICC solution  delivered via Arkessa’s multi-network MVNO platform will help underpin data sovereignty strategies as well as providing commercial and technical flexibility. - We will take advantage of Arkessa’s MVNO capabilities, underpinned by Ericsson’s Device Connection Platform and Gemalto’s On Demand Connectivity (ODC)  solution to build-in a global roaming profile for default and backup connectivity as a managed service layer over the local mobile network operators that Brighter may choose as local partners. What’s more, the remote management services around Gemalto’s eSIM will allow us to localise or customise the connectivity services according to local regulations, geographic and commercial requirements once in the field. The assurance this provides lets Brighter focus on what we do best which is mobile healthcare. says Henrik Norström, COO at Brighter.  - Diabetes is a serious and escalating problem for society with the World Health Organisation predicting that diabetes will be one of the primary causes of death by 2030 and the cost of treating Diabetes already exceeding $670 billion per year.  Brighter is brilliantly positioned to make a positive impact with their Actiste product and we are delighted to enable their global expansion and deploy another Arkessa eUICC solution, says Andrew Orrock, CEO at Arkessa. - We are pleased that our strategic engagements with global/international OEM´s are leading to business agreements for our operator partners offering Connectivity Management as a Service. Our partnership with Brighter and leading telecom operators will enable an improved and more efficient healthcare sector benefitting both patients and society, in which individuals, in this case diabetes patients, are empowered to better manage their health and wellbeing.”, says Jeff Travers, Head of IoT-Connectivity Management at Ericsson. - Technology is revolutionizing the way we manage healthcare, especially for those with chronic conditions such as diabetes. It’s expected that there will be 50million connected healthcare devices by 2021, fueled by the mass adoption of the Internet of Things. Collecting, exchanging and storing data securely is a vital part of enabling patients to take control of their own medication and simplifies interaction with healthcare staff. Through Gemalto’s eSIM  and ODC platform we are providing the most efficient solution enabling simple and reliable communication for the greater benefits of patients who will enjoy the best connectivity, says Benoit Jouffrey, Vice President of Connectivity and Embedded Solutions at Gemalto. For more information, please contact: Henrik Norström, COO, BrighterTelephone: +46 733 40 30 45Email: henrik.norstrom@brighter.se Andrew Orrock, CEO, ArkessaTelephone: +44 1279 799270Email: andrew.orrock@arkessa.com Ericsson Media Relationsmedia.relations@ericsson.com(+46 10 719 69 92) About Brighter AB (publ)"Driving Behavioral Change in Healthcare™"Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of the most serious healthcare problems: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop™ - is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and close associates, healthcare providers, research, pharmaceutical industry and society. www.brighter.se About ActisteBrighter's solution Actiste® handles most of the self-monitoring and treatment of insulin-treated diabetes in a single easy-to-use device. Measurement of glucose levels, insulin injection, and automatic logging and timing of all activity are done in a single unit. When Actiste is connected via an autonomous and secure mobile connection, the information can be automatically shared with selected recipients through The Benefit Loop™, Brighter's open cloud-based service where data is collected, processed and analyzed. Validated user-generated data, such as as test results, can be automatically transferred electronically to many different constituents. The patient selects when and how data is shared and who will have access to it. Through The Benefit Loop®, different services can motivate patients with chronic illnesses to change their behavior, which can save lives, reduce relatives' concerns, and release enormous healthcare resources. www.actiste.com About ArkessaArkessa is a global M2M managed services provider making Internet of Things (IoT) connectivity easier and future-proof. Arkessa connects devices and services to the IoT, regardless of location, network operator or wireless technology. www.arkessa.com/euicc    About EricssonEricsson provides high performing solutions for Networks, IT & Cloud, and Media. The company provides infrastructure, services and software to the telecom industry and other sectors. Ericsson has approximately 110,000 employees with customers in more than 180 countries. www.ericsson.com/en/internet-of-things  The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com. This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CET on December 13, 2017.

Nordea Open Banking is live

During the autumn, Nordea’s Open Banking team has worked together with more than 1,000 external developers, who have tested and given feedback on the open APIs and associated services. Nordea is now ready for the next step as the bank today connects the APIs to the production system and takes the first major step into the brand new world of Open Banking. This makes Nordea the first Nordic bank to offer its pilots access to real customer data. - The new PSD2 regulation will fundamentally change banking. It is not a fad. Banking will be different as from 2018, when banks have to open up to third parties to offer services to account holders, says Erik Zingmark, Co-Head of Transaction Banking at Nordea. - We view PSD2 as an opportunity, which is why we have made a significant effort in building the Open Banking platform. We see possibilities to offer our customers new services together with partners, and we could offer our customers services in geographies beyond our home region. Nordea is now starting a piloting period in which selected third parties will build applications on top of the APIs and, together with pilot customers, they will confirm that all aspects of the Open Banking solution work as expected. Pilot data is currently limited to our Finnish customers, but will soon be expanded to include customers throughout the other Nordic countries. - Together with fintechs and other external developers we aim to create new products and services for our customers at a faster pace than we could do by ourselves, while keeping customers firmly in control of what data they wish to expose and which products they wish to use, says Claus Richter, Head of Cash Management Solutions at Nordea. - That hard work has paid off, and we are proud to be the first Nordic bank to offer our pilots access to real customer data. The third-party applications will be able to use the Account Information Service (AIS) API where they can retrieve account information details and initiate payments through the Payment Initiation Service (PIS) API. The end users will be able to authenticate themselves, giving consent to the third-party provider to access their accounts. Introducing selected pilot participants to customer data in this limited way will enable Nordea to work closely with the third parties and continue to receive their feedback and improve the services. More selected third parties will, on a rolling basis, be included throughout 2018.  For further information:Claes Eliasson, Acting Head of Group External Communications, +46 72 141 67 12Gunnar Berger, Head of Open Banking +46 70 433 10 90

Ninja Casino gets triple nomination for 2018 EGR Nordics Awards

Ninja Casino has been shortlisted for the ceremony’s headline award Nordics Operator of the Year, as well as Casino Operator of the Year and Best Marketing Campaign. The online casino continues to set the benchmark with its no registration platform and lightning quick payments. This year also saw the launch of its biggest marketing campaign  to date, rolling out several high-octane TV and radio advertisements across Sweden and Finland’s major media outlets. The company will be hoping for success once again at the prestigious award ceremony, after Ninja Casino picked up the award for best In-House Innovation  at the 2017 event. The award ceremony takes place at the Corinthia Hotel St. George's Bay, Malta on the 18th January. The full shortlist for all the categories can be viewed here . In addition, Global Gaming has been shortlisted for best Payment Processing Company at the International Gaming Awards, which takes place at Grosvenor House, London on the 5th February 2018. Stefan Olsson, CEO at Global Gaming, said: “To receive not one but three nominations is a fantastic achievement for us, especially for an event which is highly regarded for recognising those who set the standards in the Nordics. “Plus, with Global Gaming being shortlisted for the International Gaming Awards in February, it’s a great way to end what has been a successful year for us. Hopefully we’ll be able to turn a few of those nominations into actual silverware, and make space for what already is a packed trophy cabinet!”

Pandox AB (publ) signs lease agreements for Hotel BLOOM! and Hotel Berlaymont in Brussels with NH Hotel Group

“We are very pleased to sign two new lease agreements with NH Hotel Group, which is a well-renowned and skillful international hotel operator and a strong business partner. The hotel market in Brussels has historically been dominated by management agreements and these lease agreements are therefore breaking new ground. The lease agreements are competitive and demonstrate that Pandox, by being active across the value-chain, creates tangible value for the company and its shareholders.”, says Martin Creydt, Senior Vice President, Property Management International at Pandox. The lease agreements with NH Hotel Group imply shared investments, lower risk and a lower yield requirement for the newly leased hotel properties. The outlook for growth in rental income and net operating profit are good. Hotel Berlaymont was acquired in May 2017. It is a full-service hotel with 214 rooms and a competitive meeting product with a strong location close to the European Commission, and good communications to the city and airport in Brussels. Hotel BLOOM! was acquired 2005 and is a full-service hotel with 305 rooms, substantial conference capacity and a central location in Brussels.    FOR MORE INFORMATION, PLEASE CONTACT: Anders Nissen, CEO, +46 (0) 708 46 02 02Martin Creydt, Senior Vice President, Property Management International, +46 (0) 708 71 35 23Anders Berg, Head of Communications and IR, +46 (0) 760 95 19 40 The information was submitted for publication on 13 December 2017 at 12:20 CET. About PandoxPandox is a leading owner of hotel properties in Northern Europe with a focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio currently comprises 122 hotels with approximately 27,000 hotel rooms in eleven countries. Pandox’s business is organised into Property management, which comprises hotel properties leased on a long-term basis to market leading regional hotel operators and leading international hotel operators, and Operator activities, which comprises hotel operations executed by Pandox in its owner-occupied hotel properties. Pandox was founded in 1995 and the company’s B shares are listed on Nasdaq Stockholm. www.pandox.se  About NH Hotels GroupNH Hotel Group  is a world-leading urban hotel operator and a consolidated multinational player. It operates close to 400 hotels and almost 60,000 rooms in 31 markets across Europe, the Americas and Africa, including top city destinations such as Amsterdam, Barcelona, Berlin, Bogota, Brussels, Buenos Aires, Düsseldorf, Frankfurt, London, Madrid, Mexico City, Milan, Munich, New York, Rome and Vienna.

Pandox AB (publ) acquires hotel portfolio in the UK and Ireland with Fattal Hotels Group as operating partner

“The acquisition fulfils all Pandox’s strategic criteria regarding countries, cities and locations, as well as size, segment and profitability, contributing to a further diversification of our revenue base. The hotel properties are of high quality, belong to the profitable upper mid-market segment and will bring an immediate and substantial contribution to earnings. Through the acquisition, Pandox adds 20 new hotel cities to the portfolio and achieves a considerable market presence in the UK and the Republic of Ireland, which are large and dynamic hotel markets. The acquisition demonstrates Pandox’s ability to execute on its business strategy in international competition and grow with good profitability also in new markets.”, says Anders Nissen, CEO of Pandox. “We are proud to continue consolidating and developing our collaboration with Pandox, our strong expansion partner. The mutual trust we have built up over the last few years forms the basis for our success. For us, the acquisition of Jurys Inn hotels represents a huge step forward in our growth. With this, we have the opportunity to further expand and strengthen our expertise and brand awareness in Europe. We look forward to this new challenge.”, says David Fattal, CEO of Fattal Hotels Group. Drivers for the acquisition 1. The hotel properties fit well into Pandox’s acquisition strategy and contribute immediately and positively to Pandox’s earnings and cash flow. 2. The hotel property portfolio is consistently of high quality and comprises 21 full-service hotels in the upper-mid market segment with a total of 4,694 rooms and an average size of approximately 224 rooms. The hotels are recently renovated with very positive guest reviews. 3. Pandox will be established in 20 new hotel markets and gains a considerable market presence in the UK and Ireland  (*) Based on GBP/SEK 11.29, which is used throughout this press release.   4. The hotels’ locations and market positions are consistently strong with exposure to major flows and geographic proximity to important communication hubs, businesses and leisure activities. 5. The hotel property portfolio, including the operating property, has a yield of approximately 5.8 percent and the acquisition price per room corresponds to approximately MSEK 1.6. 6. The demand is derived mainly from domestic business and leisure travellers (e.g. Birmingham, Manchester, Leeds and Sheffield) and is complemented in many markets by considerable international demand (e.g. London, Dublin, Manchester, Glasgow and Belfast). The hotel properties complement Pandox’s existing portfolio well in terms of demand and segmentation. 7. The 20 investment properties will be operated by Leonardo under 25-year revenue-based lease agreements with minimum guaranteed rent and shared investments, which is at the core of Pandox’s business model. The minimum guaranteed rent amounts to approximately 83 percent based on estimates for 2018. 8. The operating property will be operated by Pandox under the brand Hilton Garden Inn. The hotel has 364 rooms and is located at London Heathrow Airport. 9. Pandox estimates that the portfolio offers good potential from recently completed renovations, which have not yet taken full effect, and an increased focus on revenue management.  Transaction structure, acquisition price and financingThe seller is a company owned by Lone Star. The buyer is Pandox AB via a wholly-owned subsidiary. The transaction comprises a portfolio of 37 hotel businesses, whereby Pandox, following a reorganisation of the hotel property portfolio, retains 20 investment properties in the UK and the Republic of Ireland (see list under portfolio overview below) and one operating property in England, and whereby Leonardo acquires the operations platform with 36 hotel operations under the Jurys Inn brand. The total acquisition price amounts to 800 MGBP on a debt free basis, corresponding to approximately MSEK 9,030. The acquisition is financed by a new 5-year bank loan with Bank of America Merrill Lynch International, existing credit facilities and a loan from Leonardo in the amount of MGBP 120 to the acquiring company. After completion, a reorganisation will be implemented in accordance with a framework agreement between the parties, whereby the operational business will be transferred to Leonardo in satisfaction of the loan, after which Pandox’s share of the total acquisition price is expected to amount to MGBP 680, corresponding to approximately MSEK 7,680. During the reorganisation Leonardo will operate all Jurys Inn hotels, of which Pandox’s 20 investment properties under management agreements which correspond to revenue-based lease agreements, including minimum guaranteed rent and property commitments. These are intended to be replaced by revenue-based lease agreements at the latest by the time the reorganisation has been completed. The reorganisation is expected to be completed during 2018. The ultimate acquisition cost for Pandox is estimated at approximately MGBP 705, including costs for the reorganisation. Financial effects for Pandox at full consolidation, at current exchange rate and conditional on the transaction being completed before year-end 2017 1. For the business segment Property Management, rental income is expected to increase by approximately MSEK 440 and net operating income by approximately MSEK 425 during 2018. 2. For the business segment Operator Activities, revenues are expected to increase by approximately MSEK 130 and net operating income by approximately MSEK 25 during 2018. 3. For Pandox as a whole cash earnings are expected to increase by approximately MSEK 200 during 2018. 4. The hotel property portfolio, including the operating property, has a yield of approximately 5.8 percent. 5. Pandox’s responsibility for future investments is limited to major technical installations and building structure. 6. Pandox sees potential to, in close cooperation with Leonardo, make future cash flow enhancing investments in the acquired hotel property portfolio. 7. Based on the market value of the hotel portfolio per 30 September 2017:a. The portfolio value increases from approximately SEK 41.0 billion to approximately SEK 48.9.b. Investment Properties’ share of the total property value increases from approximately 83 percent to approximately 85 percent.c. Pandox’s loan-to-value ratio increases from approximately 48 percent to approximately 56 percent, excluding the loan from Leonardo, which should be compared with the company’s financial target of a loan-to-value ratio in the range of 45-60 percent. 8. In the fourth quarter 2017, marginal positive contributions are expected to rental income Property Management, revenue Operator Activities, net operating income Property Management and Operator Activities respectively   Terms and completionThe acquisition is expected to be completed before year-end 2017 provided that certain customary closing conditions have been fulfilled, such as the seller’s delivery of the acquired shares to Pandox and Pandox’s payment for the shares. Financial reportingPandox will consolidate the 21 hotel properties to 100 percent and report 20 under the business segment Property Management and one under the business segment Operator Activities, from the time of completion of the acquisition. See below for a list of the hotel properties. The assets and liabilities attributed to the business, which will be divested to Leonardo, will be reported in the balance sheet as Assets held for sale and Debt related to assets held for sale until the ownership of these assets is transferred to Leonardo. Portfolio overviewThe hotel property portfolio comprises 21 hotels in 20 cities, of which thirteen are in England, three in the Republic of Ireland, two in Scotland, one in Wales and one in Northern Ireland with a total of 4,694 rooms. All the investment properties are managed under the Jurys Inn brand and the operating property is managed under the Hilton Garden Inn brand. The hotels are full-service hotels in the upper mid-market segment with mainly local demand (Birmingham, Leeds and Sheffield) and elements of international demand (London, Dublin, Manchester, Cardiff and Belfast), which complements Pandox’s existing portfolio well. The hotels have strong central locations for the business, conference and leisure segments. The portfolio acquisition provides Pandox with a considerable market coverage in the fifth largest hotel market in Europe, as measured in the number of guest nights, and a geographical area with a total population of approximately 70 million. The hotels have consistently strong central locations in cities forming part of larger urban areas (*).     +-------------------+----------+-------------+----------+------------+--------+|Hotel |Country |City |Population|No. of rooms|Location|| | | |in | | || | | |city area | | || | | |(*) | | |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn London |England  |Croydon  |9,896,000 |240  |City  ||Croydon  | | | | | |+-------------------+----------+-------------+----------+------------+--------+|Hilton Garden Inn |England |London |As above |364 |Airport ||London Heathrow | | | | | ||(**) | | | | | |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn |England  |Birmingham  |2,488,200 |445  |City  ||Birmingham  | | | | | |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn |England  |Manchester  |2,434,100 |265  |City  ||Manchester  | | | | | |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Dublin |Ireland  |Dublin  |1,350,000 |182  |City  ||Christchurch  | | | | | |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Glasgow  |Scotland  |Glasgow  |980,800  |321  |City  |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn |England  |Sheffield  |830,500  |259  |City  ||Sheffield  | | | | | |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Leeds  |England  |Leeds  |774,100  |248  |City  |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Cork |Ireland |Cork |543,000 |133 |City |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Bradford |England |Bradford |531,200 |198 |City |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Belfast |Northern |Belfast |479,100 |190 |City || |Ireland | | | | |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn |England |Middlesbrough|469,600 |132 |City ||Middlesbrough | | | | | |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Cardiff |Wales |Cardiff |357,200 |142 |City |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Brighton |England |Brighton |348,700 |210 |City ||Waterfront | | | | | |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Galway |Ireland |Galway |258,000 |130 |City |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn East |England |Derby |254,300 |164 |Airport ||Midlands Airport | | | | | |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Swindon |England |Swindon |217,200 |229 |City |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Oxford |England |Oxford |159,600 |240 |City |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn |England |Cheltenham |115,000 |122 |City ||Cheltenham | | | | | |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Hinckley |England |Hinckley |50,000 |362 |City ||Island | | | | | |+-------------------+----------+-------------+----------+------------+--------+|Jurys Inn Inverness|Scotland |Inverness |50,000 |118 |City |+-------------------+----------+-------------+----------+------------+--------+|Total |5 countrie|20 cities |22,586,600|4,694 |NM || |s | | | | |+-------------------+----------+-------------+----------+------------+--------+ (*) Source: Centre For Cities, NRS Scotland, Central Statistics Office Ireland, Eurostat(**) Will be reported under the business segment Operator Activities  Invitation to telephone conference Following the acquisition, Pandox invites investors, analysts and media to a webcasted telephone conference 13 December 2017, at 15:00 CET.To follow the presentation online go to https://edge.media-server.com/m6/p/maqryztx. To participate in the conference and ask questions, please call one of the telephone numbers indicated below about 10 minutes before the start of the presentation. The presentation material will be made available at www.pandox.se. Sweden: +46(0)850653942 (Tollfree 0200883464)UK: +44 (0)3303369411 (Tollfree 08002797204)Ireland: +353(0)12465621 (Tollfree 1800936686)US: +17205430214 (Tollfree 8002817973)Confirmation code: 2238260 A recorded version of the telephone conference will be available at www.pandox.se.   FOR MORE INFORMATION, PLEASE CONTACT: Anders Nissen, CEO, +46 (0) 708 46 02 02Liia Nõu, CFO, +46 (0) 702 37 44 04Anders Berg, Head of Communications and IR, +46 (0) 760 95 19 40   This information is information that Pandox AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above on 13 December 2017 at 14:40 CET.   About PandoxPandox is a leading owner of hotel properties in Northern Europe with a focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio currently comprises 122 hotels with approximately 27,000 hotel rooms in eleven countries. Pandox’s business is organised into Property management, which comprises hotel properties leased on a long-term basis to market leading regional hotel operators and leading international hotel operators, and Operator activities, which comprises hotel operations executed by Pandox in its owner-occupied hotel properties. Pandox was founded in 1995 and the company’s B shares are listed on Nasdaq Stockholm. www.pandox.se About Fattal Hotel GroupFattal Hotel Group is a leading Middle East and European hotel operator. Fattal was founded by career hotelier, David Fattal, in 1998 and the business has become synonymous with innovation within the hospitality sector. Fattal operates 126 hotels in 14 countries. Over the past decade, Fattal expanded its operations into Europe where it now manages 88 hotels across Europe with 45 in Germany and 7 hotels under the Leonardo brand in the UK. About Jurys InnJurys Inn is a hotel group founded in Ireland that believes that every guest deserves to ‘Stay Happy’. There are 36 hotels operating under the Jurys Inn brand and they are known for their warm, friendly service and convenient locations within easy reach of top attractions, amenities and transport hubs. About Lone StarLone Star is a leading global private equity firm that invests globally in real estate, equity, credit and other financial assets. Since the establishment of its first fund in 1995, Lone Star has organized seventeen private equity funds with aggregate capital commitments totaling over $70 billion.

LINK Mobility Group ASA enters the Swiss market by acquiring the SMS messaging business in Switzerland currently operated by Horisen AG

LINK Mobility Group ASA ("LINK"), one of Europe's leading and fastest growing providers of B2C mobile messaging and mobile services, has today entered into a definitive agreement for the acquisition of the Swiss mobile messaging business ("Horisen Messaging") from the Swiss mobile messaging company Horisen AG. Horisen AG was established in 2001, and is located in Rorschach, Switzerland. Horisen Messaging has a strong position in the Swiss market and is one of the leading mobile messaging providers in Switzerland with a strong footprint delivering services to more than 175 countries globally. "I am really happy to announce that we have acquired Horisen Messaging the leading mobile messaging provider in Switzerland with more than 30% market share and a strong international network. We look forward to become the leading mobile messaging and solutions provider in Switzerland and to continue developing the Swiss market with existing and new services going forward." says Arild E. Hustad, CEO of LINK. "I am very happy that our messaging customers will be in very good hands with LINK Mobility in the future and that HORISEN AG can now focus 100% on its software business. This transaction is a real win-win situation for LINK Mobility and HORISEN AG. I am also very pleased that LINK Mobility decided to continue using for HORISEN Messaging AG the award-winning messaging platform software of HORISEN AG, to take advantage of its powerful features thus strengthen its competitiveness in the messaging business" says Fabrizio Salanitri, CEO of HORISEN AG. The transaction will be structured as an acquisition by LINK of Horisen Messaging AG, a carve-out from Horisen AG, that upon closing will hold the Horisen Messaging business. The agreed enterprise value of the transaction is EUR 9.0 million, on a cash-free and debt-free basis. The enterprise value is based on a normalized EBITDA for 2017 of EUR 1.8 million multiplied by a factor of 5. The purchase price under the transaction will, subject to customary adjustments, be settled as follows: - 57% of the purchase price in cash upon closing, - 43% of the purchase price in shares upon closing The transaction is expected to close on 5 January 2018. The cash part of the transaction will be fully financed through LINK's corporate fund and bond. Aabø-Evensen & Co Advokatfirma AS and Ernst & Young AG, Switzerland has acted as legal advisors to LINK Mobility Group ASA in connection with the transaction.

Textile revolution on the dress of the Nobel peace prize winner – Unique embroideries at the Nobel Peace Prize concert

These unique embroideries are made with more than half a million stitches of 4000 meter Embroline thread softly changing colour from green to blue. With this dress Beatrice is the first person in the world to carry Embroline embroideries in public, apart from embroideries shown by Coloreel at events, fairs and catwalks. The founder of Coloreel, Joakim Staberg, says “It has been a great honour for us to be able to contribute with our thread colouring technology to a dress worn at such a prominent occasion”. The Coloreel technology enables a high-quality instant colouring of textile thread while the thread is being used in textile production. The first product to be launched based on this technology is Embroline, a groundbreaking thread colouring attachment that can be used with any existing embroidery machine. By instantly colouring a white base thread during the embroidery production, Embroline enables complete freedom to create unique embroideries without any limitations in the use of colours. Colour changes along the thread can be made rapidly from one solid colour to another or gradually, to make smooth transitions or any colouring effect you can imagine. Bahareh says “Embroline opens up entirely new ways of creating embroideries that have not been possible before. The embroideries on Beatrice’s dress is a great example of this. Embroline is definitely the future of embroidery”. Beatrice agrees and adds “I also really cherish the environmental benefits that comes along with this innovative thread colouring technology”. For more information about Coloreel and Embroline, visit www.coloreel.comor contact:  Magnus Hellström, VP Sales & Marketing, magnus.hellstrom@coloreel.com, +46 709 501 620 Joakim Staberg, Innovator and Founder, joakim.staberg@coloreel.com, +46 708 502 502 The Nobel Peace Prize is the most prestigious award in the world, honoring icons such as Martin Luther King, Jr., Mother Teresa, Nelson Mandela, Mikhail Gorbachev, Archbishop Desmond Tutu and other remarkable individuals and organizations.

Scania invests SEK 1.5 billion in energy-efficient foundry

“In the ongoing shift towards a fossil-free society, even more energy-efficient combustion engines as well as combustion engines that operate on biofuels and gas will be needed. In particular for trucks and buses in long distance transport. The new foundry will be instrumental in providing such engines,” says Ruthger de Vries, Executive Vice President, Head of Production and Logistics at Scania. The investment in a completely new foundry is one of Scania’s largest single investments in an entirely new industrial plant. The investment decision was preceded by a comprehensive analysis of various alternatives, such as increased purchasing from external suppliers or a conversion and extension of the existing foundry.  “A completely new plant is the most cost-efficient solution and the best alternative from an environmental and quality standpoint when it comes to the future supply of strategically important parts for our engine production. Through this investment, we will also retain important proximity to our research and development organisation, which is concentrated in Södertälje. Meanwhile, this means that Södertälje will continue to be the hub for our European engine production,” says de Vries. Heat recovery and more efficient materials handling The energy usage per tonne produced in the new foundry is expected to be 50 percent lower than in the existing facility. The largest energy gains will be obtained through improvements in the casting process and recovery of the heat this generates.  With the introduction of new methods for materials handling and recycling, transports will also be reduced in relation to the number of units produced. The largest single energy saving will be achieved through recycling of the sand used in production of casting moulds, so-called cores, where it will be possible to recycle 70 percent of the sand. The technology used in the current foundry does not permit any sand recycling. The sand is transported long distances by truck. These transports will not increase despite a tripling of production volume. “From a sustainability perspective, this means that we will reduce the use of a finite resource while the climatic impact from sand transports will not increase despite a tripling of production volume,” says de Vries. Strong consideration for local environmental impacts Scania’s decision to invest in a completely new foundry was based on consideration of the local environmental impact in the form of noise and emissions from the operations and also from goods transport services. The current foundry, which was constructed in 1914, is located in an industrial estate close to central Södertälje, while the new plant will be built in one of the outlying areas of the city at Tveta industrial estate, situated west of the E20 route. In line with the realisation of the plans to improve the road transport infrastructure in Södertälje, including a new connection to the E20 motorway, it will be possible to further reduce the local environmental impact from Scania’s goods transport services in the future. The planning of the land for the new foundry in Södertälje will begin after the necessary environmental impact assessment is concluded, which is expected to happen during spring 2018, and the start of construction is planned for January 2019. At full capacity utilisation, the new foundry will employ the same number of people as the existing foundry, i.e. almost 200 employees. For further information, please contact Hans-Åke Danielsson, Press Manager, phone +46 08 553 856 62, e-mail hans-ake.danielsson@scania.com

Nordic Capital acquires a majority stake in Ryds Bilglas

Ryds Bilglas is one of the leading vehicle glass repair and replacement companies in Sweden and is also active in the Norwegian market. The company was founded in Sundsvall, Sweden by the Ryd family in 1947, has annual revenues of c. SEK 700 mn and has more than 100 workshops with over 350 employees. The market for vehicle glass repair and replacement is attractive and growing. Ryds Bilglas holds a strong market position in Sweden, with a robust platform catering for high customer satisfaction. Nordic Capital will support the Company’s continued growth strategy through further investments to strengthen its commercial excellence work, operational improvements and initiatives in digitalisation. "Ryds Bilglas has a very experienced management team and a market-leading position which provides a solid platform for growth. The Company has a high-quality service offering and very high customer satisfaction. We share the Ryd family’s ambition to leverage on these attributes and expand the business. Nordic Capital has a long history and proven track record of growing businesses and looks forward to supporting the management team in its next phase," says Andreas Näsvik, Partner at the Advisor to the Nordic Capital Funds. "We have a period of strong growth behind us evidenced by the doubling of our sales in Sweden in the last five years. We have established a presence in Norway and we are in the process of expanding into Denmark. With Nordic Capital supporting the Company as new owners, we believe we will have the muscles needed to further strengthen our Nordic expansion," says Anders Jensen, CEO, Ryds Bilglas. "We in the Ryd family are very positive about our upcoming cooperation with Nordic Capital. We have cooperated with Nalka Invest for five years with great success and we anticipate further strong growth for Ryds Bilglas and that the collaboration with Nordic Capital will be successful," says Leif Ryd, representative of the founding family Ryd. Nordic Capital has had a high level of transactional activity in 2017, having completed the take private of Nordnet, a pan-Nordic digital savings platform; the combination of Lindorff with listed Intrum to create the global industry leader in credit management services; and the IPOs of Handicare and Munters on Nasdaq Stockholm. The acquisition of Ryds Bilglas further builds on this momentum for the Nordic Capital Funds, which have made eleven successful exits including six IPOs and eight new platform investments in the last two years including MFEX and Nordax in Sweden and Alloheim in Germany. The parties have agreed not to disclose the financial terms of the transaction. The investment is subject to approval by the relevant authorities. Media contacts: Katarina Janerud, Communications ManagerAdvisor to the Nordic Capital FundsTel: +46 8 440 50 50e-mail: katarina.janerud@nordiccapital.com Anders Jensen, CEORyds BilglasTel. +46 70 727 34 80e-mail: anders.jensen@rydsbilglas.se About Ryds Bilglas Ryds Bilglas is one of the market leaders in Sweden for the repair and replacement of automotive glasses. The business is represented with close to 100 workshops in Sweden, and 16 in Norway. In addition to its own workshops, there is also a network of franchisees under the brand name Samglas, which is a wholly owned subsidiary. For more information, please see www.rydsbilglas.se.  About Nordic Capital Nordic Capital is a leading private equity investor in the Nordic region with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a proven track record. Core sectors are Healthcare, Technology & Payments, Financial Services, Industrial Goods & Services and Consumer & Retail, and key regions are the Nordics, Northern Europe, and globally for Healthcare. Since inception in 1989, Nordic Capital has invested EUR 11 billion through eight funds. The Nordic Capital Funds are based in Jersey and are advised by advisory entities, which are based in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital please see www.nordiccapital.com

NCC to build Global Business Gate in Gothenburg

“Together with NCC, we are now commencing the work on Global Business Gate, which will be an innovative hub and a meeting place for the export industry and global specialist companies working in international business. We have been working on this project a long time, and are very pleased that we have now begun collaborating with a contractor for the actual implementation,” says Lennart Hedström, CEO of Global Business Gate. The project consists of two buildings, totaling 40,000 square meters, that will be built on a new peninsula stretching approximately 100 meters out into Göta Älv in the Masthuggskajen district in central Gothenburg. Global Business Gate, which is owned half by Elof Hansson Properties and half by the occupational pension provider Alecta, has signed a partnering agreement with NCC for the project. Together, the parties will complete the task in the form of a transparent and solution-oriented cooperation, with a focus on the best interests of the project. “Partnering is built on the same principles as team sports. Common goals, clear tactics and a closely knit team for the best possible result. Global Business Gate is one of the largest ventures for the business sector in Gothenburg over the next few years, and it’s great to have the opportunity to be a part of the project and run it as a shared partnering business,” says Henrik Landelius, Head of NCC Building Sweden. The project has been divided into two phases, in which the parties will first produce program documentation, system documentation and project scheduling. The second phase will concentrate on continued project engineering and construction. Global Business Gate is expected to be completed in 2021. The total order value of the project is estimated at approximately SEK 900 million, and is expected to be registered among orders in September 2018, when the parties sign the agreements for phase two. The transaction will be registered in the NCC Building business area.

WTX101 granted Fast Track designation by the U.S. FDA for the treatment of Wilson Disease

Wilson Therapeutics AB (publ), today announced that the U.S. Food and Drug Administration (FDA) has granted WTX101 Fast Track designation for the treatment of Wilson Disease. The FDA’s Fast Track program is designed to facilitate the development, and expedite the review of novel therapies to treat serious conditions and fill an unmet medical need. WTX101 (bis-choline tetrathiomolybdate) is a first-in-class copper-protein-binding agent with a unique mechanism of action, under investigation as a novel therapy for Wilson Disease. “We are extremely pleased to receive Fast Track designation from the FDA, which supports our view that WTX101 can address significant unmet medical needs in this rare and debilitating disease. The Fast Track designation also provides a number of regulatory advantages, including additional access to the FDA which can speed up the future review of WTX101 and help bring this drug to patients as quickly as possible”, commented Wilson Therapeutics CEO Jonas Hansson. The Fast Track Designation is supported by data from the 24-week open label multicenter Phase 2 trial in patients with Wilson Disease (WTX101-201), which was conducted by Wilson Therapeutics. The study showed that once-daily dosing of WTX101 has the potential to rapidly lower and control free copper, improve or stabilize neurological and liver status and improve patient-reported disability. Furthermore, no cases of initial drug-induced neurological worsening upon treatment initiation have been observed to date. An open-label extension study is ongoing, and the company expects to enroll the first patient in the Phase 3 FOCuS trial in early 2018. About Fast Track designationFast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions that address an unmet medical need, by providing a therapy where none exists or providing a therapy which may be potentially better and shows some advantage over available therapy. Fast Track designation includes opportunities for more frequent meetings with the FDA to discuss trial design, development plans, data needed to support drug approval, submission of a New Drug Application (NDA) on a rolling basis and eligibility for accelerated approval and priority review, if relevant criteria are met. Visit FDA’s website  for more information About WTX101 (bis-choline tetrathiomolybdate)WTX101 (bis-choline tetrathiomolybdate) is a first-in-class copper-protein-binding agent with a unique mechanism of action, under investigation as a novel therapy for Wilson Disease. In contrast to current treatments, WTX101 provides an alternative copper-protein binding mechanism by forming a tripartite complex with copper and albumin. WTX101 thereby detoxifies excess copper in both liver and blood, and promotes copper clearance through biliary excretion (the body’s natural route of elimination). A Phase 2 study evaluating the efficacy and safety of WTX101 in patients with Wilson Disease has successfully been completed. In addition, the active moiety of WTX101, tetrathiomolybdate, has been tested in several previous clinical studies in Wilson Disease patients. The data from these studies suggest that WTX101 can lower and control free copper levels, and improve symptoms and associated disabilities. The data also suggest that WTX101 is generally well tolerated with a low risk of neurological worsening. The tolerability profile and the expected once-daily dosing regimen have the potential to improve compliance in Wilson Disease patients, leading to fewer treatment failures and ultimately improved outcomes. WTX101 has received orphan drug designation for the treatment of Wilson Disease in the US and EU. In addition, WTX101 has shown potential as a treatment for several other medical conditions including Amyotrophic Lateral Sclerosis (ALS). WTX101 has received US orphan drug designation for the treatment of ALS. About Wilson DiseaseCopper is an essential trace element that plays a critical role in key physiological cellular processes. Due to its toxic potential, copper is normally tightly bound to copper-carrying proteins inside the liver, and excess copper is eliminated from the body via biliary excretion. Wilson Disease is a rare genetic disorder of impaired copper transport and excretion, caused by loss of function of the ATP7B copper-binding protein. This leads to copper overload in the liver, release of free copper into the blood, and damaging accumulation of copper in the brain and other organs. Untreated Wilson Disease inevitably leads to various combinations and severity of hepatic, neurologic and psychiatric symptoms, and is ultimately fatal. Wilson Disease affects approximately one in every 30,000 people worldwide, corresponding to a prevalence of approximately 10,000 patients in the US and 15,000 patients in the EU. The therapies currently being used in Wilson Disease were introduced in the 1950s and 60s. Since then, no new treatment options have been developed and considerable unmet medical needs still exist. About Wilson TherapeuticsWilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. Visit www.wilsontherapeutics.com for more information. For further information contact:Jonas Hansson, CEO, Wilson Therapeutics ABTelephone: +46 8 796 00 00Email: jonas.hansson@wtx.se Wilson Therapeutics AB (publ)Corp. Reg. No.556893-0357Kungsgatan 3SE-111 43 Stockholm The information in the press release is information that Wilson Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on December 14, 2017.

Autoliv receives award from Fiat Chrysler Automobiles for work on future urban car safety

Autoliv received the award together with Zenuity, its system software joint venture. “We are incredibly proud to receive this award. It proves that Autoliv’s vision of Saving More Lives and Zenuity’s of Make it Real means so much more than words. In a short timespan we have provided products, solutions and expertize that have made it possible for FCA to go from concept to demo of its vision of future urban car safety”, said Johan Löfvenholm, President, Autoliv Electronics. “In the end this is what matters – delivering real solutions to real customers that enables them to realize their visions,” he continued. Autoliv and Zenuity received the award for their implementation of active safety hardware and software that enabled a number of advanced active safety and ADAS features in a small form factor vehicle, hence making it supremely safe in urban environments. Today 50% of all accidents occurs in urban traffic, and with the on-going urbanization this number is expected to continue to grow. Reducing urban accidents is one of the prime focus areas for traffic authorities, OEM’s and safety suppliers around the world. Inquiries: Thomas Jönsson, Group Vice President, Corporate Communications.    Tel +46 (0)8 5872 0627 About Autoliv Autoliv, Inc. is the worldwide leader in automotive safety systems, and through its subsidiaries develops and manufactures automotive safety systems for all major automotive manufacturers in the world. Together with its joint ventures, Autoliv has more than 80 facilities with 70,000 employees in 27 countries. In addition, the Company has 22 technical centers in ten countries around the world, with 19 test tracks, more than any other automotive safety supplier. Sales in 2016 amounted to about US $10.1 billion. The Company's shares are listed on the New York Stock Exchange (NYSE: ALV) and its Swedish Depository Receipts on Nasdaq Stockholm (ALIV sdb). For more information about Autoliv, please visit our company website at www.autoliv.com. Safe Harbor Statement This report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any such statements in light of new information or future events, except as required by law.

SenzaGen reports positive results from ring trial in the validation of GARDskin™

The comprehensive laboratory evaluation of GARDskin, which is required for final regulatory validation, has produced excellent results. Three independent laboratories (Eurofins BioPharma Product Testing in Germany, Burleson's Research Technologies in the United States and SenzaGen's own laboratory in Lund) have carried out blind analyses of a large number of chemicals. The process has been repeated on several different occasions, in accordance with the OECD validation process. The purpose is to validate the transferability, robustness and reproducibility of the test, in order to demonstrate that GARDskin can deliver reliable results with higher accuracy than existing tests, even when used in external laboratories. The results will be presented in detail at SOT, the International Society of Toxicology Conference, in Texas in March, and subsequently in scientific publications. "The validation study provides convincing evidence that GARDskin works well even when the test method is used in external laboratories. The results reinforce the scientific basis for GARDskin in the process of obtaining regulatory approval and inclusion in international test guidelines. We are delighted with the outcome which shows that GARD consistently outperforms all existing validated test methods," says SenzaGen's CEO, Anki Malmborg Hager. The results from the completed validation study constitute an important part of the basis for the forthcoming evaluation of SenzaGen's tests in the ECVAM Scientific Committee and within the OECD. Regulatory approval and recommendation on the use of GARDskin are expected from the OECD in April 2019. GARDpotency™, which is based on the same biological platform, is being validated in parallel with GARDskin, and is thus expected to be approved and recommended at the same time. GARDskin will have significant potential to meet the increasing demand in the cosmetics, chemicals and pharmaceutical industries for reliable, animal-free testing methods to assess the allergy-inducing properties of chemical substances. For more information:Anki Malmborg Hager, CEO, SenzaGen ABEmail: anki.malmborg.hager@senzagen.comTelephone: +46 768 284822 About GARDGARD™ is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently, GARD™ tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods. About SenzaGenSenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com This information is information that SenzaGen is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above on the 14 December 2017 at 08:30. SenzaGen AB are listed on Nasdaq First North in Stockholm and FNCA is the company’s Certified Adviser. For more information, please visit www.senzagen.com

Deutsche Telekom selects Ericsson for 5G-ready network

Faster, safer, and more stable – To offer customers an even better customer experience, Deutsche Telekom is modernizing its mobile network with 5G-ready multi-standard solutions in Germany. For this important step towards 5G, Deutsche Telekom has selected Ericsson (NASDAQ: ERIC) as supplier for its current and future network in one out of two market areas of Deutsche Telekom in Germany. The modernized network will bring improved network performance experience to subscribers. Ericsson will modernize Deutsche Telekom’s 2G, 3G and 4G network with a multi-standard solution. This deal is a five-year agreement that will include delivering a multi-standard Radio Access Network, based on Ericsson’s Baseband 6630 product and multi-standard radios, Ericsson Network Manager  for OSS, as well as hardware and software support and services. In this context, the OSS for the radio network enables unified network management. Arun Bansal, Senior Vice President and Head of Market Area Europe and Latin America, says: “We listened to Deutsche Telekom and understood their urgency to have 5G-ready infrastructure in order to stay at the forefront of customer service in Germany. We can run multiple standards on the same baseband hardware and a 5G upgrade will be able to be performed by a simple software download to the radio sites. And, during these deliveries, we will use the experience from our 5G activities around the world to be sure that Deutsche Telekom has the most advanced hardware and software in the industry.” Deploying the 5G-ready radio access network infrastructure marks a new chapter of collaboration between Ericsson and Deutsche Telekom. Ericsson has been a trusted partner for Deutsche Telekom´s 2G network and IP telephony network (Mobile and Fixed). “Now, we are expanding our partnership and building a foundation for a joint journey towards 5G,” says Arun Bansal. NOTES TO EDITORS For media kits, backgrounders, and high-resolution photos, please visit www.ericsson.com/press FOLLOW US: www.twitter.com/ericssonwww.facebook.com/ericssonwww.linkedin.com/company/ericssonwww.youtube.com/ericsson  MORE INFORMATION AT: News Center  media.relations@ericsson.com(+46 10 719 69 92) investor.relations@ericsson.com(+46 10 719 00 00) Ericsson is a world leader in communications technology and services with headquarters in Stockholm, Sweden. Our organization consists of more than 111,000 experts who provide customers in 180 countries with innovative solutions and services. Together we are building a more connected future where anyone and any industry is empowered to reach their full potential. Net sales in 2016 were SEK 222.6 billion (USD 24.5 billion). The Ericsson stock is listed on Nasdaq Stockholm and on NASDAQ in New York. Read more on www.ericsson.com.

SAS appoints new Chief Financial Officer and increases its focus on key strategic ventures

This new structure will provide a platform for SAS to further strengthen the relationship with our customer base and secure a fleet development that meets the evolving demand for business and leisure travel among Scandinavia’s frequent travelers. In this new capacity, Göran will continue as Deputy President and member of SAS Group Management. Torbjørn Wist is a Norwegian citizen with extensive knowledge and international experience from the financial services industry and telecoms industry, holding multiple financial leadership positions in the US, UK and Norway. Most recently, Torbjørn has served as Group Treasurer for Telenor ASA since 2012. In addition to his responsibilities as SAS CFO, Torbjørn Wist will also function as SAS senior representative and spokesperson in Norway. "I am very pleased to welcome Torbjørn to SAS. His solid financial experience , coupled with his experience from the fast-moving telecoms industry, makes him a valuable addition to SAS Group Management and our strive to further strengthen SAS in a highly competitive market. I’m also pleased that Göran Jansson, with his in-depth knowledge of SAS and the aviation industry, will continue in a new capacity to further accelerate our strategic ventures.”, says CEO Rickard Gustafson”. "I am very happy and proud to join the strong team at SAS under the leadership of President and CEO, Rickard Gustafson. I look forward to working with the team and relevant stakeholders to drive future results and value creation within Scandinavia's leading airline, said newly appointed CFO of SAS, Torbjørn Wist”. Torbjørn Wist will take office after SAS’ annual general shareholders meeting (AGM) in March 2018. Göran Jansson will continue in his current position until then. För further information: SAS pressjour, tel +46 8 797 29 44Björn Tibell, Head of Investor Relations, +46 70 997 1437

Saab and NTU Singapore Have Signed Master Research Collaboration Agreement

The agreement was signed by NTU President Professor Bertil Andersson, and Saab Executive Vice President and Deputy CEO Micael Johansson at NTU Singapore. It follows the Memorandum of Understanding that was signed in Stockholm on 18 October this year.  “This is an important step for Saab, heavily expanding our research internationally. NTU is one of the world’s best technology universities and we are very happy to be able to start this important collaboration together with them,” said Micael Johansson, Executive Vice President and Deputy CEO at Saab. The two current focus areas for the research collaboration to be conducted at the Saab-NTU Joint Research Centre will be air traffic management projects, such as investigating the possibility of employing artificial intelligence and machine learning to augment the capability of air traffic controllers, and also underwater robotic research, to enable underwater autonomous vehicles to navigate relative to its surrounding objects. “This collaboration allows Saab and NTU to leverage each other capabilities. NTU’s strengths in interdisciplinary research, together with Saab’s expertise in aeronautics and defence technology can create important synergies that could lead to the development of innovative technologies that will benefit both industry and society,” said Prof Andersson. For further information, please contact: Saab Press Centre, +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com www.saabgroup.com/YouTube Follow us on Twitter: @saab Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs.

Catena Media acquires Squawka.com and related assets from Squawka Ltd.

The main site currently attracts ca 4 million users per month, and has around 800 000 followers on Twitter. The purchase price amounts to a one-time upfront payment of GBP 1 million (approximately EUR 1.1 million) to be paid through cash consideration. The acquisition is expected to generate annual sales of approximately EUR 2 million with an estimated 60% margin. Catena Media will add its knowledge in building successful affiliate sites to the high-volume, quality Squawka site. Background and rationaleThrough the acquisition of the assets in Squawka, Catena Media will further strengthen its offering within the sports betting segment, particularly in the football vertical. Integration will commence immediately upon completion of the transaction and it includes a team of 4 employees that will relocate to Catena Media’s London office and form part of Catena Media’s Sports division. Squawka and its related sites currently only generate revenues through banner advertising. “We see potential for Squawka as a high-volume traffic site with a global audience, to which we look forward to implementing an affiliation business model. The company has invested in automatic data feeds for their user-friendly graphical interfaces, which is something we aim to integrate into other Catena Media products. Squawka will sit alongside our existing brands, increasing our coverage in the football vertical while entering the upcoming sports year”, says Henrik Persson Ekdahl, Acting CEO, Catena Media. Terms and description of the transactionThe transfer of all Squawka’s assets and payment of consideration is scheduled to take place mid-December. The purchase price amounts to an upfront payment of GBP 1 million (approximately EUR 1.1 million), which is being paid as a cash consideration in conjunction with the transfer of the assets.About Squawka UK-based Squawka was founded in 2012 and has built up a strong brand with high preference in its target group. Squawka has invested time and resources in the UX/code for presenting statistics and offers a user friendly interface. Revenue is currently generated solely through the sale of banner advertising on sites including www.squawka.com and the DFS site, www.matchboss.com. The existing team consists of 4 employees based in the UK. For further information, please contact: Henrik Persson Ekdahl, Acting CEOPhone: +46 706 91 43 43E-mail: henrik.persson@catenamedia.comwww.catenamedia.com The information was submitted for publication on December 14, 2017 at 15:00 CET. About Catena Media Catena Media plc is an online performance marketing company that has established a leading position through strong organic growth and acquisitions.  The business was started in 2012 and the group has approximately 245 employees in the US, Australia, Japan, Serbia, UK, and Malta, where the Head Office is situated. In 2016, revenues reached approximately EUR 40 million. The company is listed on Nasdaq Stockholm Mid Cap. Further information is available at www.catenamedia.com

PAYDAY 2™: RESERVOIR DOGS HEIST OUT NOW

Starbreeze Studios and OVERKILL – A Starbreeze Studio have announced the release of the latest content for PAYDAY 2 – the “Reservoir Dogs Heist” DLC – available today as a free update on Steam for all owners of PAYDAY 2: Ultimate Edition. Known for its snappy dialogue, cool characters and humor, the masterpiece Reservoir Dogs is now a playable part of PAYDAY 2. To celebrate the movie’s 25th anniversary, OVERKILL and Starbreeze Studios have created a Reservoir Dogs heist based on the film. The “Reservoir Dogs Heist” comes with the following: · A 2-Day Heist named “PAYDAY 2: Reservoir Dogs Heist”. · Weapon - Union 5.56 Rifle · Melee Weapon - Alabama Razor · 3 Masks: The Dons, Producers and Futuras. Check out the website here: http://www.overkillsoftware.com/games/reservoirdogs/ Watch the trailer: https://youtu.be/lIdAG7aJoSM With more than 5.4 million community members on the PC digital distribution platform Steam, PAYDAY 2 has had more than 160 paid and free updates since its release in 2013. First launched in 2011, PAYDAY is a cooperative first-person shooter computer and video game franchise with more than 16 million units sold on PC, SteamOS, PlayStation®3, Xbox 360, Playstation®4 and Xbox One. PAYDAY 2 VR is now also available in beta for HTC Vive and other headsets on Steam. ### Download the latest press assets for PAYDAY 2: Reservoir Dogs Heist here: http://www.starbreeze.com/presskit 

Tele2 and Deutsche Telekom to combine their Dutch operations

A value creating transaction for customers and shareholdersThe transaction combines two mobile customer champions with complementary brands, technologies and customer bases. Tele2 will own 25% of the new company and T-Mobile’s ownership will amount to 75%. Based on current numbers the company will have around 5 million mobile pre- and post-paid customers, combined revenues of around EUR 2 billion and synergies estimated at an NPV of more than EUR 1 billion. As a part of the agreement, a cash payment of EUR 190 million will be made to Tele2 upon closing. The transaction crystallizes value created in the Dutch market to date and will de-risk the Dutch asset for the Tele2 Group, going forward. Consolidation as a path to enable further investments and innovationTele2 and T-Mobile are now competing against two players controlling more than 80% of the Dutch mobile and fixed telecommunications market. The combination of Tele2 and T-Mobile into one company will create a stronger customer champion and secures investment capacity for new products and new technologies, such as 5G. Allison Kirkby, President and CEO of Tele2 AB, comments: “This is a fantastic opportunity to speed up development of the Dutch telco market and to spur effective competition to the benefit of the Dutch population. This enlarged company builds on the great momentum we have built since relaunching Tele2 in November 2015 and on the network sharing that we have had with T-Mobile since 2013. I see this as a logical next step to create a stronger number three FMC player that will benefit our customers, our shareholders and our employees”. Jon James, CEO of Tele2 Netherlands, comments: “Tele2 has been on a remarkable journey in the Dutch market, building a great brand and a world-class network. Our combination with T-Mobile brings together two companies with complementary approaches and strengths to create a stronger competitor to the FMC duopoly which will shake up the telecoms market – both for consumers and businesses”. Business as usualWhile we seek the necessary regulatory approval, there will be no change for the customers of Tele2 and T-Mobile. Tele2 will continue with its stand-alone strategy and to invest behind its propositions for consumers and businesses. In the longer term this transaction will enable accelerated investments into new products and technologies to the benefit of Dutch consumers and businesses. FinancingThe combined company is expected to be capitalized with an intercompany loan receivable by Deutsche Telekom of approximately EUR 1.1 billion. Looking forward, the shareholders have agreed on a dividend policy that includes a pay-out ratio of 70% of free cash flow to be initiated when the Net Debt to EBITDA is below 2.5x. Deutsche Telekom will retain its Dutch tower assets in a separate entity. The parties have also amended the National Roaming Agreement and the Network Sharing Agreement. GovernanceThe Supervisory Board will consist of 3 members appointed by Deutsche Telekom, 1 by Tele2 and 1 by the Works Council. Regulatory processThe establishment of the combined company is subject to regulatory approval by the relevant competition authorities. The transaction is therefore expected to close in the second half of 2018. Tele2 will revert with more information on the regulatory timeline and process when it is available. As a part of the agreement, there is a break fee amounting to EUR 25 million that Tele2 will receive, in case the transaction should not be approved by the relevant authorities. Effects on financial reportingTele2 Netherlands will be reported as a discontinued operation in the period until closing. In the fourth quarter of 2017 Tele2 will conclude the annual impairment test. Notwithstanding the incremental value created in the transaction, the test is estimated to result in an impairment of SEK 1.0-1.5 billion related to the Dutch operation. The amount will be reported under discontinued operations and has no effect on cash flow. Press and analyst conference callTele2 will host an press and analyst conference call at 08:30 CET (07:30 GMT/2:30 EST time). The conference call will be held in English and also made available as a webcast through www.tele2.com Dial-in information:To ensure that you are connected to the conference call, please dial in a few minutes before the start of the conference call to register your attendance. Dial-in numbersNL: +31 (0)20 703 8261SE: +46 (0)8 5065 3942UK: +44 (0)330 336 9411US: +1 323-794-2093 Confirmation code: 5252698 For more information, please contact: Angelica Gustafsson, Head of Public Relations, Tele2 AB, Phone: +46 704 26 41 42 Erik Strandin Pers, Head of Investor Relations, Tele2 AB, Phone: +46 733 41 41 88 The information is of such character, which Tele2 AB (publ) shall disclose in accordance with the Securities Market Act (2007:528) and/or the law on Trading with Financial Instruments (1991:980). The information was distributed for disclosure at 07:00 CET on 15 December 2017. TELE2’S MISSION IS TO FEARLESSLY LIBERATE PEOPLE TO LIVE A MORE CONNECTED LIFE. We believe the connected life is a better life, and so our aim is to make connectivity increasingly accessible to our customers, no matter where or when they need it. Ever since Jan Stenbeck founded the company in 1993, it has been a tough challenger to the former government monopolies and other established providers. Tele2 offers mobile services, fixed broadband and telephony, data network services, content services and global IoT solutions. Every day our 17 million customers across 8 countries enjoy a fast and wireless experience through our award winning networks. Tele2 has been listed on the NASDAQ OMX Stockholm since 1996. In 2016, Tele2 had net sales of SEK 28 billion and reported an operating profit (EBITDA) of SEK 5.3 billion. For definitions of measures, please see the last pages of the Annual Report 2016. Follow @Tele2group on Twitter for the latest updates.

Invitation: Press and analyst conference call

Tele2 will host a press and analyst conference call at 08:30 CET (07:30 GMT/02:30 EST). The conference call will be held in English and also made available as a webcast at Tele2’s website www.tele2.com. Dial-in informationTo ensure that you are connected to the conference call, please dial in a few minutes before the start of the conference call to register your attendance. Dial-in numbersNL: +31 (0)20 703 8261SE: +46 (0)8 5065 3942UK: +44 (0)330 336 9411US: +1 323-794-2093 Confirmation code: 5252698 For more information, please contact:Angelica Gustafsson, Head of Public Relations, Tele2 AB, Phone: +46 704 26 41 42Erik Strandin Pers, Head of Investor Relations, Tele2 AB, Phone: +46 733 41 41 88 TELE2’S MISSION IS TO FEARLESSLY LIBERATE PEOPLE TO LIVE A MORE CONNECTED LIFE. We believe the connected life is a better life, and so our aim is to make connectivity increasingly accessible to our customers, no matter where or when they need it. Ever since Jan Stenbeck founded the company in 1993, it has been a tough challenger to the former government monopolies and other established providers. Tele2 offers mobile services, fixed broadband and telephony, data network services, content services and global IoT solutions. Every day our 17 million customers across 8 countries enjoy a fast and wireless experience through our award winning networks. Tele2 has been listed on the NASDAQ OMX Stockholm since 1996. In 2016, Tele2 had net sales of SEK 28 billion and reported an operating profit (EBITDA) of SEK 5.3 billion. For definitions of measures, please see the last pages of the Annual Report 2016. Follow @Tele2group on Twitter for the latest updates.

The H&M group’s sales development for the full-year 2017 including the fourth quarter 2017

In the fourth quarter of 2017, i.e. during the period 1 September 2017 to 30 November 2017, sales including VAT amounted to SEK 58,454* m (61,098). Sales excluding VAT amounted to SEK 50,390* m (52,720), a decrease of 4 percent compared to the corresponding quarter last year. In local currencies, sales decreased by 2 percent. The H&M group continued to grow during the year. However, the growth was dampened by the fact that the sales development in the fourth quarter was significantly below the company’s own expectations. The H&M brand’s online sales and sales of the group’s other brands continued to develop well. Meanwhile, the quarter was weak for the H&M brand’s physical stores, which were negatively affected by a continued challenging market situation with reduced footfall to stores due to the ongoing shift in the industry. In addition, there have been imbalances in parts of the H&M brand’s assortment composition. In order to correct this, a number of actions have been taken. Moreover, the management team of the H&M brand has recently been strengthened. In order to respond even quicker to customers’ fast-changing behaviour the company’s ongoing transformation journey is being accelerated. Among other things, this includes continued integration of the physical and digital stores, and intensifying the optimisation of the H&M brand’s store portfolio – leading to more store closures and fewer openings. Full-year report and capital markets dayThe full-year report for 2017, i.e. 1 December 2016 to 30 November 2017, will be published at 08:00 CET on 31 January 2018, followed by a press conference and a telephone conference. During the capital markets day in Stockholm on 14 February 2018, which is intended for institutional investors, analysts and financial media, the H&M group will present the ongoing transformation journey in more detail. Karl-Johan Persson, CEO *The amounts are provisional and may deviate slightly from the full-year report, covering the period 1 December 2016 – 30 November 2017, that will be published on 31 January 2018.

Management change in Telia Company

“I’m very grateful for the dedicated work that Robert has done for Telia Company. His broad international experience from the telecommunications industry has proven itself invaluable for me and the company on our journey towards becoming a New Generation Telco. I wish him all the best in Finland where he now resides and is ready for new challenges,” says Johan Dennelind, President and CEO of Telia Company.   Robert Andersson joined Telia Company and the Group Executive Management in 2012 when he was appointed CEO of Sonera, Telia’s Finnish operations. In 2013, Robert Andersson was appointed Head of Region Europe which included all Nordic and Baltic operations outside of Sweden, as well as Yoigo in Spain. Under his leadership Telia Company consolidated and expanded its operations in Estonia, Lithuania and Norway and gained strong market positions.    In December 2016, Robert Andersson was appointed Head of Corporate Holdings – a new unit which managed Telia Company’s significant shareholding at the time in Turkcell and Megafon (today only an indirect stake in Turkcell), Telia Company’s Latvian operations and Telia Carrier – a global leading internet backbone provider.   “I have really enjoyed the time at Telia Company where I have had the pleasure of working with great people in different parts of the organization and countries. I believe that Telia Company is well prepared to face the fast changing nature of our industry and I am proud to be able to say that I have contributed to laying the strong foundation that the company rests on today.”   Robert Andersson, who will not be replaced, will stay with Telia Company for a period of time to ensure a proper hand over of his responsibilities to current members of the Group Executive Management Team.      For more information, please contact our press office +46 771 77 58 30, visit our Newsroom  or follow us on Twitter @Teliacompany .        We’re Telia Company, the New Generation Telco. Our 21,000 talented colleagues serve millions of customers every day in one of the world’s most connected regions. With a strong connectivity base, we’re the hub in the digital ecosystem, empowering people, companies and societies to stay in touch with everything that matters 24/7/365 - on their terms. Headquartered in Stockholm, the heart of innovation and technology, we’re set to change the industry and bring the world even closer for our customers. Read more at www.teliacompany.com               

Loudspring carries out a directed share issue of approximately EUR 1.26 million (approximately SEK 12.5 million)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, SOUTH AFRICA OR JAPAN OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Loudspring Oyj Company release 15.12.2017, 12:00 (EEST) Based on the authorization granted by the Annual General Meeting of the Company on 21 April 2017, the Board of Directors of Loudspring Oyj (“Loudspring” or the “Company”) have on 15 December 2017 resolved on a directed share issue of approximately EUR 1.26 million (approximately SEK 12.5 million) to Alfred Berg Kapitalförvaltning (the “Share Issue”). In the Share Issue, 475 977 new class A shares (the “Offer Shares”) were subscribed. The subscription price in the Share Issue was set at EUR 2.64 (SEK 26,26) per Offer Share and amounts to a total of approximately EUR 1.26 million (approximately SEK 12.5 million) before commissions and expenses. The entire subscription price of the Offer Shares will be recorded in the Company's reserve for invested unrestricted equity. The price in the Share Issue has been decided based on contacts with selected institutional investors and the Company considers the price agreed upon with the investor to be on market terms. The reasons for the deviation from the shareholders’ pre-emptive rights was to raise capital in a time and cost-effective manner while broadening the institutional shareholder base. The Offer Shares represent approximately 2% of the outstanding shares and 0.4% of the votes in the Company after the Share Issue. Following the Share Issue, the number of issued and outstanding A-shares of the Company will be 19,233,186. Loudspring’s Chairman of the Board Lassi Noponen: "We have decided to follow up our recent share issue with a similar fund raise directed to Alfred Berg. The share issue is priced at a favourable level which is a strong sign for our current shareholders. We will continue to increase awareness of the company in Sweden and we now have an improved base for doing so with a reputable institution such as Alfred Berg as our shareholder, as well as additional capital to execute on our recent strategy update.”  Loudspring’s CEO Alexander Bigge Lidgren comments: “Turning wasted natural resources into revenues is at the heart and center of the strong market growth we are clearly seeing in our companies. We are well positioned to capture a large part of it by increasing our ownership in our current high performers and with this additional capital we will continue to build a number of global leaders in their respective fields.” The Offer Shares are expected to be registered in the Finnish Trade Register on or about 22 December 2017. Loudspring will apply for listing of the Offer Shares on Nasdaq First North Stockholm and Helsinki. Expected first day of trading in the Offer Shares is 22 December 2017. Pareto Securities is acting as Sole Manager and Bookrunner in connection with the Share Issue. Loudspring Oyj Board of Directors Important information This announcement is not an offer to sell or a solicitation of any offer to buy or subscribe for any securities issued by Loudspring Oyj (the "Company") in any jurisdiction where such offer or sale would be unlawful. In any EEA Member State that has implemented Directive 2003/71/EC as amended (together with any applicable implementing measures in any member State, the “Prospectus Directive”), the securities referred to in this release may only be offered in a member state (a) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) in any other circumstances falling within Article 3(2) of the Prospectus Directive. The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, South Africa or Japan. This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” (as defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it. No prospectus will be made available in connection with the matters contained in this announcement and no such prospectus is required (in accordance with the Prospectus Directive) to be published. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new shares. Any investment decision to buy or subscribe for new shares in the share issue must be made solely on the basis of publicly available information, which has not been independently verified by Pareto Securities (the "Manager"). The Manager is acting for the Company in connection with the transaction and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the transaction or any other matter referred to herein. The information in this announcement may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction or disclosure of this information in whole or in part is unauthorised. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions. This announcement does not constitute an invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities in any jurisdiction. This announcement does not constitute a recommendation concerning any investor’s option with respect to the share issue. Each investor or prospective investor should conduct his, her or its own investigation, analysis and evaluation of the business and data described in this announcement and publicly available information. The price and value of securities can go down as well as up. Past performance is not a guide to future performance. Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this announcement.

Ripasso Energy share issue completed – preliminary results shows oversubscription

“We thank our shareholders for their trust. We now have all the resources in place to build a successful and profitable export company,” says Sven Sahle, Ripasso Energy AB’s Chairman of the Board and largest shareholder. For additional information related to this press release, please contact Ripasso Energy’s Chairman of the Board Sven Sahle at ir@ripassoenergy.com. For additional information about the company, please visit www.ripassoenergy.com . You can also sign up for the company’s newsletter on the website.  Ripasso Energy is a Swedish cleantech company founded in 2008 to further develop the Stirling technology’s outstanding ability to convert heat energy into electricity. The company offers different solutions for power generation at record low prices, compared to other climate-smart and sustainable alternatives. Ripasso Energy’s Stirling engine has unofficial world record in converting solar energy to electricity with close to twice as high efficiency as competitive technologies. The company is listed in Sweden (NGM Nordic MTF), and can also be traded at Börse Stuttgart in Germany. Read more at www.ripassoenergy.com .  THIS PRESS RELEASE MAY NOT BE PUBLICISED, PUBLISHED OR DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE AND SOUTH AFRICA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL.